99 results on '"Fontaine, JF"'
Search Results
2. Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control
- Author
-
Caimmi, D., Baiz, N., Tanno, L. K., Demoly, P., Arnavielhe, S., Murray, R., Bedbrook, A., Bergmann, K. C., De Vries, G., Fokkens, W. J., Fonseca, J., Haahtela, T., Keil, T., Kuna, P., Mullol, J., Papadopoulos, N., Passalacqua, G., Samolinski, B., Tomazic, P. V., Valiulis, A., van Eerd, M., Wickman, M., Annesi‐Maesano, I., Bousquet, J., Agache, I, Angles, R, Anto, JM, Asayag, E, Bacci, E, Bachert, C, Baroni, I, Barreto, BA, Bedolla‐Barajas, M, Bertorello, L, Bewick, M, Bieber, T, Birov, S, Bindslev‐Jensen, C, Blua, A, Bochenska Marciniak, M, Bogus‐Buczynska, I, Bosnic‐Ancevich, S, Bosse, I, Bourret, R, Bucca, C, Buonaiuto, R, Caiazza, D, Caillot, D, Caimmi, DP, Camargos, P, Canfora, G, Cardona, V, Carriazo, AM, Cartier, C, Castellano, G, Chavannes, NH, Ciaravolo, MM, Cingi, C, Ciceran, A, Colas, L, Colgan, E, Coll, J, Conforti, D, Correira de Sousa, J, Cortés‐Grimaldo, RM, Corti, F, Costa, E, Courbis, AL, Cruz, A, Custovic, A, Dario, C, da Silva, M, Dauvilliers, Y, De Blay, F, Dedeu, T, De Feo, G, De Martino, B, Di Capua, S, Di Carluccio, N, Dray, G, Dubakiene, R, Eller, E, Emuzyte, R, Espinoza‐Contreras, JM, Estrada‐Cardona, A, Farrell, J, Ferrero, J, Fontaine, JF, Forti, S, Gálvez‐Romero, JL, Garcia Cruz, MH, García‐Cobas, CI, Gemicioğlu, B, Gerth van Wijck, R, Guidacci, M, Gómez‐Vera, J, Guldemond, NA, Gutter, Z, Hajjam, J, Hellings, P, Hernández‐Velázquez, L, Illario, M, Ivancevich, JC, Jares, E, Joos, G, Just, J, Kalayci, O, Kalyoncu, AF, Karjalainen, J, Khaltaev, N, Klimek, L, Kull, I, Kuna, TP, Kvedariene, V, Kolek, V, Krzych‐Fałta, E, Kupczyk, M, Lacwik, P, Larenas‐Linnemann, D, Laune, D, Lauri, D, Lavrut, J, Lessa, M, Levato, G, Lewis, L, Lieten, I, Lipiec, A, Louis, R, Luna‐Pech, JA, Magnan, A, Malva, J, Maspero, JF, Mayora, O, Medina‐Ávalos, MA, Melen, E, Menditto, E, Millot‐Keurinck, J, Moda, G, Morais‐Almeida, M, Mösges, R, Mota‐Pinto, A, Muraro, A, Noguès, M, Nalin, M, Napoli, L, Neffen, H, OʼHehir, R, Olivé Elias, M, Onorato, G, Palkonen, S, Pépin, JL, Pereira, AM, Persico, M, Pfaar, O, Pozzi, AC, Prokopakis, EP, Raciborski, F, Rizzo, JA, Robalo‐Cordeiro, C, Rodríguez‐González, M, Rolla, G, Roller‐Wirnsberger, RE, Romano, A, Romano, M, Salimäki, J, Serpa, FS, Shamai, S, Sierra, M, Sova, M, Sorlini, M, Stellato, C, Stelmach, R, Strandberg, T, Stroetman, V, Stukas, R, Szylling, A, Tibaldi, V, Todo‐Bom, A, Toppila‐Salmi, S, Tomazic, P, Trama, U, Triggiani, M, Valero, A, Valovirta, E, van Eerd, M, Vasankari, T, Vatrella, A, Ventura, MT, Verissimo, MT, Viart, F, Williams, S, Wagenmann, M, Wanscher, C, Westman, M, Young, I, Yorgancioglu, A, Zernotti, E, Zurbierber, T, Zurkuhlen, A, De Oliviera, B, and Senn, A
- Published
- 2017
- Full Text
- View/download PDF
3. Adherence to treatment in allergic rhinitis using mobile technology. the mask study
- Author
-
Menditto, E, Costa, E, Midao, L, Bosnic-Anticevich, S, Novellino, E, Bialek, S, Briedis, V, Mair, A, Rajabian-Soderlund, R, Arnavielhe, S, Bedbrook, A, Czarlewski, W, Annesi-Maesano, I, Anto, JM, Devillier, P, De Vries, G, Keil, T, Sheikh, A, Orlando, V, Larenas-Linnemann, D, Cecchi, L, De Feo, G, Stellato, C, Fonseca, J, Malva, J, Morais-Almeida, M, Pereira, AM, Todo-Bom, AM, Kvedariene, V, Valiulis, A, Bergmann, KC, Klimek, L, Mosges, R, Pfaar, O, Zuberbier, T, Cardona, V, Mullol, J, Papadopoulos, NG, Prokopakis, EP, Bewick, M, Ryan, D, Roller-Wirnsberger, RE, Tomazic, PV, Cruz, AA, Kuna, P, Samolinski, B, Fokkens, WJ, Reitsma, S, Bosse, I, Fontaine, JF, Laune, D, Haahtela, T, Toppila-Salmi, S, Bachert, C, Hellings, PW, Melen, E, Wickman, M, Bindslev-Jensen, C, Eller, E, O'Hehir, RE, Cingi, C, Gemicioglu, B, Kalayci, O, Ivancevich, JC, Bousquet, J, Aberer, W, Agache, I, Akdis, CA, Akdis, M, Aliberti, MR, Almeida, R, Amat, F, Angles, R, Ansotegui, IJ, Arnavielle, S, Asayag, E, Asarnoj, A, Arshad, H, Avolio, F, Bacci, E, Baiar-Dini, I, Barbara, C, Barbagallo, M, Baroni, I, Barreto, BA, Basagana, X, Bateman, ED, Bedolla-Barajas, M, Beghe, B, Bel, EH, Bennoor, KS, Benson, M, Bertorello, L, Bialoszewski, AZ, Bieber, T, Bjermer, L, Blain, H, Blasi, F, Blua, A, Marciniak, MB, Bogus-Buczynska, I, Boner, AL, Bonini, M, Bonini, S, Bosnic-Anticevich, CS, Bouchard, J, Boulet, LP, Bourret, R, Bousquet, P, Braido, F, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Buonaiuto, R, Panaitescu, C, Cabanas, MTB, Burte, E, Bush, A, Caballero-Fonseca, F, Caillaud, D, Caimmi, D, Calderon, MA, Camargos, PAM, Camuzat, T, Canfora, G, Canonica, GW, Carlsen, KH, Carreiro-Martins, P, Carriazo, AM, Carr, W, Cartier, C, Casale, T, Castellano, G, Cepeda, AM, Chavannes, NH, Chen, Y, Chiron, R, Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciaravolo, MM, Ciceran, A, Ciprandi, G, Coehlo, ACC, Colas, L, Colgan, E, Coll, J, Conforti, D, De Sousa, JC, Cortes-Grimaldo, RM, Corti, F, Mc Costa-Dominguez, Al Courbis, Cox, L, Crescenzo, M, Custovic, A, Dahlen, SE, D'Amato, Dario, C, da Silva, J, Dauvilliers, Y, Darsow, U, De Blay, F, De Carlo, G, Dedeu, T, Emerson, MDF, De Martino, B, Rubina, NPM, Deleanu, D, Demoly, P, Denburg, J, Ercolano, SDC, Di Carluccio, N, Didier, A, Dokic, D, Dominguez-Silva, MG, Douagui, H, Dray, G, Dubakiene, R, Durham, SR, Du Toit, G, Dykewicz, MS, El-Gamal, Y, Eklund, P, Emuzyte, R, Farrell, J, Farsi, A, De Mello, JF, Ferrero, J, Fink-Wagner, A, Fiocchi, A, Fok-Kens, WJ, Forti, S, Fuentes-Perez, JM, Galvez-Romero, JL, Gamkrelidze, A, Garcia-Aymerich, J, Garcia-Cobas, CY, Garcia-Cruz, MH, Genova, S, Christoff, G, Gereda, JE, Van Wijk, RG, Gomez, RM, Gomez-Vera, J, Diaz, SG, Gotua, M, Grisle, I, Guidacci, M, Guldemond, N, Gutter, Z, Guzman, M, Hajjam, J, Hernandez, L, Houri-Hane, J, Huerta-Villalobos, YR, Humbert, M, Iaccarino, G, Illario, M, Ispayeva, Z, Jares, E, Jassem, E, Johnston, SL, Joos, G, Jung, KS, Just, J, Jutel, M, Kaidashev, I, Kalyoncu, AF, Karjalainen, J, Kardas, P, Keith, PK, Khaitov, M, Khaltaev, N, Kleine-Tebbe, J, Kowalski, ML, Kuitunen, M, Kull, I, Kupczyk, M, Krzych-Falta, E, Lacwik, P, Lauri, D, Lavrut, J, L, TT, Lessa, M, Levato, G, Li, J, Lieberman, P, Liplec, A, Lipworth, B, Carlsen, KCL, Louis, R, Lourenco, O, Luna-Pech, JA, Magnan, A, Mahboub, B, Maier, D, Majer, I, Mandajieva, E, Manning, P, Keenoy, EDM, Marshall, GD, Masjedi, MR, Maspero, JF, Mathieu-Dupas, E, Campos, JJM, Al Matos, Maurer, M, Mavale-Manuel, S, Mayora, O, Medina-Avalos, MA, Melo-Gomes, E, Meltzer, E, Mercier, J, Miculinic, N, Mihaltan, F, Milenkovic, B, Moda, G, Mogica-Martinez, MD, Mohammad, Y, Momas, I, Monte-Fort, S, Monti, R, Bogado, DM, Morato-Castro, Mota-Pinto, A, Santo, PM, Munter, L, Muraro, A, Murray, R, Naclerio, R, Nadif, R, Nalin, M, Napoli, L, Namazova-Baranova, L, Neffen, H, Niedeberger, V, Nekam, K, Neou, A, Nieto, A, Nogueira-Silva, L, Nogues, M, Nyembue, T, O'Hehir, R, Odzhakova, C, Ohta, K, Okamoto, Y, Okubo, K, Onorato, GL, Cisneros, MO, Ouedraogo, S, Pali-Scholl, I, Palkonen, S, Panzner, P, Park, HS, Papi, A, Passalacqua, G, Paulino, E, Pawankar, R, Pedersen, S, Pepin, JL, Persico, M, Phillips, J, Picard, R, Pigearias, B, Pin, I, Pitsios, C, Plavec, D, Pohl, W, Popov, TA, Portejoie, F, Potter, P, Pozzi, AC, Price, D, Puy, R, Pugin, B, Ross, REP, Przemecka, M, Rabe, KF, Raciborski, F, Raja-Bian-Soderlund, R, Ribeirinho, I, Rimmer, J, Riv-Ero-Yeverino, D, Rizzo, JA, Rizzo, MC, Robalo-Cordeiro, C, Rodenas, F, Rodo, X, Gonzalez, MR, Rodriguez-Manas, L, Rolland, C, Valle, SR, Rodriguez, MR, Romano, A, Rodriguez-Zagal, E, Rolla, G, Romano, M, Rosado-Pinto, J, Rosario, N, Rottem, M, Sagara, H, Salimaki, J, Sanchez-Borges, M, Sastre-Dominguez, J, Scadding, GK, Schunemann, HJ, Scichilone, N, Schmid-Grendelmeier, P, Serpa, FS, Shamai, S, Sierra, M, Simons, FER, Sir-Oux, V, Sisul, JC, Skrindo, I, Sole, D, Somekh, D, Sonder-Mann, M, Sooronbaev, T, Sova, M, Sorensen, M, Sorlini, M, Spranger, O, Stelmach, R, Stukas, R, Sunyer, J, Strozek, J, Szylling, A, Tebyrica, J, Thibaudon, M, To, T, Todo-Bom, A, Trama, U, Triggiani, M, Ulrik, CS, Urrutia-Pereira, M, Valenta, R, Valero, A, Valovirta, E, Van Eerd, M, Van Ganse, E, Van Hague, M, Vandenplas, O, Ventura, MT, Vezzani, G, Vasankari, T, Vatrella, A, Verissimo, MT, Viart, F, Viegi, G, Vicheva, D, Vontetsianos, T, Wagenmann, M, Walker, S, Wallace, D, Wang, DY, Waserman, S, Werfel, T, Westman, M, Williams, DM, Williams, S, Wilson, N, Wright, J, Wroczynski, P, Yakovliev, P, Yawn, BP, Yiallouros, PK, Yorgancioglu, A, Yusuf, OM, Zar, HJ, Zhang, L, Zhong, N, Zernotti, ME, Zhanat, I, Zidarn, M, Zubrinich, C, Zurkuhlen, A, MASK Grp, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Department of Dermatology, Allergology and Venereology, University of Helsinki, Clinicum, Children's Hospital, HUS Children and Adolescents, HUS Inflammation Center, et. al., Universidade do Minho, Internal Medicine, Health Services Management & Organisation (HSMO), Ear, Nose and Throat, AII - Inflammatory diseases, Kyomed, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Università degli Studi di Salerno (UNISA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto, Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University of Cologne, Department of Otorhinolaryngology, Head, and Neck Surgery, University Hospital Leuven, Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Cerrahpasa Faculty of Medicine, Istanbul University, Hacettepe University = Hacettepe Üniversitesi, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department for Molecular Biomedical Research, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Department of Otorhinolaryngology, Head and Neck Surgery, Eskisehir Osmangazi University, Instituto de Biologia Molecular e Celular (IBMC), Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), UCB Pharma, Colombes, Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department of Dermatology and Allergy Centre, Odense University Hospital, Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], German Society for Otorhinolaryngology HNS, Medical University of Łódź (MUL), Vilnius University [Vilnius], Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), University of Coimbra [Portugal] (UC), 'Federico II' University of Naples Medical School, Transverse group for research in primary care [Barcelona], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Naples Federico II, University Hospital Mannheim, Allergy and Respiratory Research Group, University of Edinburgh, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw - Poland, Asthma UK Centre for Applied Research [Edinburgh, U.K.], University of Edinburgh-Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], Vilnius University Clinic of Children's Diseases, Sachs’ Children and Youth Hospital [Stockholm, Sweden], Secretary General of the Global Allergy and Asthma European Network (GA2LEN), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Menditto, E, Costa, E, Midão, L, Bosnic-Anticevich, S, Novellino, E, Bialek, S, Briedis, V, Mair, A, Rajabian-Soderlund, R, Arnavielhe, S, Bedbrook, A, Czarlewski, W, Annesi-Maesano, I, Anto, Jm, Devillier, P, De Vries, G, Keil, T, Sheikh, A, Orlando, V, Larenas-Linnemann, D, Cecchi, L, De Feo, G, Illario, M, Stellato, C, Fonseca, J, Malva, J, Morais-Almeida, M, Pereira, Am, Todo-Bom, A, Kvedariene, V, Valiulis, A, Bergmann, Kc, Klimek, L, Mösges, R, Pfaar, O, Zuberbier, T, Cardona, V, Mullol, J, Papadopoulos, Ng, Prokopakis, Ep, Bewick, M, Ryan, D, Roller-Wirnsberger, Re, Tomazic, Pv, Cruz, Aa, Kuna, P, Samolinski, B, Fokkens, Wj, Reitsma, S, Bosse, I, Fontaine, Jf, Laune, D, Haahtela, T, Toppila-Salmi, S, Bachert, C, Hellings, Pw, Melén, E, Wickman, M, Bindslev-Jensen, C, Eller, E, O'Hehir, Re, Cingi, C, Gemicioğlu, B, Kalayci, O, Ivancevich, Jc, Bousquet, J, and Iaccarino, Guido
- Subjects
0301 basic medicine ,Male ,Allergy ,Medicina Básica [Ciências Médicas] ,CONTROLLER MEDICATION ,adherence ,mHealth ,mobile technology ,observational study ,rhinitis ,treatment ,THERAPY ,Medical and Health Sciences ,Medical Records ,DISEASE ,0302 clinical medicine ,Surveys and Questionnaires ,Immunology and Allergy ,Middle Aged ,Mobile Applications ,3. Good health ,Medication possession ratio ,rhiniti ,1107 Immunology ,Ciências Médicas::Medicina Básica ,Female ,TRIAL ,Life Sciences & Biomedicine ,Adult ,medicine.medical_specialty ,Immunology ,K-ANONYMITY ,VALIDATION ,1117 Public Health and Health Services ,Medication Adherence ,03 medical and health sciences ,Internal medicine ,Health Sciences ,medicine ,Humans ,Clinical significance ,Mobile technology ,[INFO]Computer Science [cs] ,Asthma ,Aged ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,Science & Technology ,Relative efficacy ,business.industry ,PERSISTENCE ,medicine.disease ,Rhinitis, Allergic ,Cell Phone Use ,Patient Outcome Assessment ,030104 developmental biology ,Cross-Sectional Studies ,030228 respiratory system ,3121 General medicine, internal medicine and other clinical medicine ,MASK group ,ASTHMA ,Observational study ,business - Abstract
Pereira, Ana Margarida/0000-0002-5468-0932; Briedis, Vitalis/0000-0002-5106-6638; Johnston, Sebastian Lennox/0000-0003-3009-9200; Orlando, Valentina/0000-0002-8209-8878; Sova, Milan/0000-0002-8542-7841; Chung, Kian Fan/0000-0001-7101-1426; Ciprandi, Giorgio/0000-0001-7016-8421; Yusuf, M Osman/0000-0002-8067-1204; stelmach, rafael/0000-0002-5132-1934; Sunyer, Jordi/0000-0002-2602-4110; Martins, Pedro/0000-0002-4129-133X; Demoly, Pascal/0000-0001-7827-7964; Fonseca, Joao Almeida/0000-0002-0887-8796; Anto, J M/0000-0002-4736-8529; IACCARINO, Guido/0000-0002-8997-835X; Custovic, Adnan/0000-0001-5218-7071; Lourenco, Olga/0000-0002-8401-5976; Pugin, Benoit/0000-0001-7132-9477; Chavannes, Niels/0000-0002-8607-9199; Rodo, Xavier/0000-0003-4843-6180; Nadif, Rachel/0000-0003-4938-9339; Plavec, Davor/0000-0003-2020-8119; Vicheva, Dilyana/0000-0002-6805-3825; Iaccarino, Guido/0000-0002-8997-835X; Annesi-Maesano, Isabella/0000-0002-6340-9300; N.G., Papadopoulos/0000-0002-4448-3468; J, Garcia-Aymerich/0000-0002-7097-4586; Humbert, Marc/0000-0003-0703-2892; Barbara, C./0000-0003-0915-4105; Gemicioglu, Bilun/0000-0001-5953-4881; Caimmi, Davide/0000-0003-4481-6194; Namazova-Baranova, Leyla/0000-0002-2209-7531; Basagana, Xavier/0000-0002-8457-1489; Midao, Luis/0000-0003-1981-2554; Sheikh, Aziz/0000-0001-7022-3056; O'Hehir, Robyn/0000-0002-3489-7595; Cardona, Victoria/0000-0003-2197-9767; Mota-Pinto, Anabela/0000-0002-0820-9568; Cecchi, Lorenzo/0000-0002-0658-2449; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Costa, Elisio/0000-0003-1158-1480; Kuna, Piotr/0000-0003-2401-0070; Malva, Joao/0000-0002-5438-4447; Zuberbier, Torsten/0000-0002-1466-8875; Toppila-Salmi, Sanna/0000-0003-0890-6686; Nogueira-Silva, Luis/0000-0002-5519-707X; Ivancevich, Juan Carlos/0000-0001-8713-6258 WOS:000463761700007 PubMed ID: 30597673 Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. Results: A total of 12143 users were registered. A total of 6949 users reported at least one VAS data recording. Among them, 1887 users reported >= 7 VAS data. About 1195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR >= 70% and PDC = 70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR
- Published
- 2019
4. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App
- Author
-
Bédard, Annabelle, Antó, Josep, Fonseca, Joao, Arnavielhe, Sylvie, Bachert, Claus, Bedbrook, Anna, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Cardona, Victoria, Cruz, Alvaro, Fokkens, Wytske, Garcia-Aymerich, Judith, Hellings, Peter, Ivancevich, Juan, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée, Melen, Erik, Monti, Ricardo, Mösges, Ralf, Mullol, Joaquim, Papadopoulos, Nikos, Pham-Thi, Nhan, Samolinski, Boleslaw, V Tomazic, Peter, Toppila-Salmi, Sanna, Ventura, Maria Teresa, Yorgancioglu, Arzu, Bousquet, Jean, Pfaar, Oliver, Basagana, Xavier, Bosnic‐Anticevich, Sinthia, Pham‐Thi, Nhân, Hellings, PW, Aberer, W., Agache, I., Akdis, Ca, Akdis, M., Aliberti, MR, Almeida, R., Amat, F., Angles, R, Annesi‐Maesano, I, Ansotegui, IJ, Anto, JM, Arnavielle, S, Asayag, E, Asarnoj, A, Arshad, H, Avolio, F, Bacci, E, Baiardini, I, Barbara, C, Barbagallo, M., Baroni, I, Barreto, BA, Basagaña, X., Bateman, ED, Bedolla‐Barajas, M, Bewick, M., Beghé, B., Bel, EH, Bergmann, KC, Bennoor, KS, Benson, M, Bertorello, L, Białoszewski, AZ, Bieber, T., Bialek, S, Bindslev‐Jensen, Carsten, Bjermer, L., Blain, H., Blasi, F., Blua, A, Bochenska Marciniak, M, Bogus‐Buczynska, I, Boner, AL, Bonini, M., Bonini, S., Bosnic‐Anticevich, CS, Bosse, I., Bouchard, J., Boulet, LP, Bourret, R., Bousquet, Pj, Braido, F, Briedis, V, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Buonaiuto, R, Panaitescu, C, Burguete Cabañas, MT, Burte, E., Bush, A, Caballero‐Fonseca, F, Caillaud, D., Caimmi, D., Calderon, MA, Camargos, PAM, Camuzat, T., Canfora, G, Canonica, Gw, Carlsen, KH, Carreiro‐Martins, P, Carriazo, AM, Carr, W, Cartier, C., Casale, T., Castellano, G, Cecchi, L, Cepeda, AM, Chavannes, NH, Chen, Y., Chiron, R., Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciaravolo, MM, Ciceran, A, Cingi, C, Ciprandi, G, Carvalho Coehlo, AC, Colas, L, Colgan, E, Coll, J, Conforti, D, Constantinidis, J, de Sousa, J Correia, Cortés‐Grimaldo, RM, Corti, F, Costa, E, Costa‐Dominguez, MC, Courbis, AL, Cox, L, Crescenzo, M, Cruz, AA, Custovic, A., Czarlewski, W., Dahlen, Se, D’Amato, G, Dario, C, Da Silva, J., Dauvilliers, Y., Darsow, U, De Blay, F., De Carlo, G, Dedeu, T, de Fátima Emerson, M, De Feo, G., De Vries, G, De Martino, B, Motta Rubini, NP, Deleanu, D, Denburg, JA, devillier, P., Di Capua Ercolano, S, Di Carluccio, N, Didier, A., Dokic, D, Dominguez‐Silva, MG, Douagui, H, Dray, G., Dubakiene, R, Durham, Sr, Du Toit, G, Dykewicz, MS, El‐Gamal, Y, Eklund, P, Eller, E, Emuzyte, R., Farrell, J, Farsi, A, de Mello, J Ferreira, Ferrero, J, Fink‐Wagner, A, Fiocchi, A, Fokkens, WJ, Fonseca, JA, Fontaine, Jf, Forti, S, Fuentes‐Perez, JM, Gálvez‐Romero, JL, Gamkrelidze, A, Garcia‐Aymerich, Judith, García‐Cobas, CY, Garcia‐Cruz, MH, Gemicioğlu, B, Genova, S, Christoff, G, Gereda, JE, Van Wijk, R Gerth, Gomez, RM, Gómez‐Vera, J, González Diaz, S, Gotua, M., Grisle, I, Guidacci, M, Guldemond, NA, Gutter, Z, Guzmán, MA, Haahtela, T., Hajjam, J, Hernández, L, Hourihane, JO’B, Huerta‐Villalobos, YR, Humbert, M., Iaccarino, G., Illario, M, Ispayeva, Z, Ivancevich, JC, Jares, EJ, Jassem, E, Johnston, Sl, Joos, G, Jung, KS, Just, J., Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, AF, Karjalainen, J, Kardas, P, Keil, T, Keith, PK, Khaitov, M, Khaltaev, N, Kleine‐Tebbe, J, Kowalski, Ml, Kuitunen, M, Kull, I., Kupczyk, M, Krzych‐Fałta, E, Lacwik, P, Larenas‐Linnemann, Désirée, Laune, D., Lauri, D, Lavrut, J, Le, LTT, Lessa, M, Levato, G, Li, J., Lieberman, P, Lipiec, A, Lipworth, B, Lodrup Carlsen, KC, Louis, R, Lourenço, O, Luna‐Pech, JA, Magnan, A., Mahboub, B, Maier, D., Mair, A, Majer, I, Malva, J, Mandajieva, E, Manning, P, De Manuel Keenoy, E, Marshall, GD, Masjedi, MR, Maspero, JF, Mathieu‐Dupas, E, Matta Campos, JJ, Matos, AL, Maurer, M, Mavale‐Manuel, S, Mayora, O, Meco, C, Medina‐Avalos, MA, Melo‐Gomes, E, Meltzer, EO, Menditto, E., Miculinic, N, Mihaltan, F., Milenkovic, B, Moda, G, Mogica‐Martinez, MD, Mohammad, Y, Momas, I., Montefort, S, Mora Bogado, D, Morais‐Almeida, M, Morato‐Castro, FF, Mota‐Pinto, A, Moura Santo, P, Münter, L, Muraro, A, Murray, R, Naclerio, R., Nadif, R., Nalin, M, Napoli, L, Namazova‐Baranova, L, Neffen, H, Niedeberger, V, Nekam, K, Neou, A, Nieto, A, Nogueira‐Silva, L, Nogues, M., Novellino, E, Nyembue, TD, O’Hehir, RE, Odzhakova, C, Ohta, K., Okamoto, Y., Okubo, K, Onorato, GL, Ortega Cisneros, M, Ouédraogo, S., Pali‐Schöll, I, Palkonen, S, Panzner, P, Papadopoulos, NG, Park, HS, Papi, A., Passalacqua, G, Paulino, E, Pawankar, R, Pedersen, S, Pépin, JL, Pereira, AM, Persico, M, PHILLIPS, J, Picard, R., Pigearias, B, Pin, I., Pitsios, C., Plavec, D, Pohl, W, Popov, TA, Portejoie, F., Potter, P, Pozzi, AC, Price, D, Prokopakis, EP, Puy, R, Pugin, B, Pulido Ross, RE, Przemecka, M, Rabe, KF, Raciborski, F, Rajabian‐Soderlund, R, Reitsma, S, Ribeirinho, I, Rimmer, J, Rivero‐Yeverino, D, Rizzo, JA, Rizzo, MC, Robalo‐Cordeiro, C, Rodenas, F, Rodo, X, Rodriguez Gonzalez, M, Rodriguez‐Mañas, L, Rolland, C, Rodrigues Valle, S, Roman Rodriguez, M., Romano, A, Rodriguez‐Zagal, E, Rolla, G, Roller‐Wirnsberger, RE, Romano, M, Rosado‐Pinto, J, Rosario, N., Rottem, M, Ryan, D, Sagara, H, Salimäki, J, Sanchez‐Borges, M, Sastre‐Dominguez, J, Scadding, GK, Schunemann, HJ, Scichilone, N, Schmid‐Grendelmeier, P, Sarquis Serpa, F, Shamai, S., Sheikh, A., Sierra, M, Simons, FER, Siroux, V., Sisul, JC, Skrindo, I, Solé, D, Somekh, D, Sondermann, M, Sooronbaev, T, Sova, M, Sorensen, M, Sorlini, M, Spranger, O, Stellato, C, Stelmach, R, Stukas, R, Sunyer, J., Strozek, J, Szylling, A, Tebyriçá, JN, Thibaudon, M., To, T., Todo‐Bom, A, Tomazic, PV, Toppila‐Salmi, Sanna, Trama, U, Triggiani, M, Suppli Ulrik, C, Urrutia‐Pereira, M, Valenta, R, Valero, A., Valiulis, A., Valovirta, E., van Eerd, M, Van Ganse, E., van Hage, M, Vandenplas, O, Ventura, MT, Vezzani, G, Vasankari, T, Vatrella, A., Verissimo, MT, Viart, F., Viegi, G., Vicheva, D, Vontetsianos, T, Wagenmann, M, Walker, S, Wallace, D, Wang, DY, Waserman, S., Werfel, T, Westman, M, Wickman, M., Williams, DM, Williams, S, Wilson, N, Wright, J, Wroczynski, P, Yakovliev, P, Yawn, BP, Yiallouros, PK, Yusuf, OM, Zar, HJ, Zhang, L., Zhong, N, Zernotti, ME, Zhanat, I, Zidarn, M, Zuberbier, T., Zubrinich, C, Zurkuhlen, A, Mercier, Jacques, Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), IMIM-Hospital del Mar, Generalitat de Catalunya, Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, KYomed INNOV, Ghent University Hospital, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Odense University Hospital [Odense, Denmark], Woolcock Institute of Medical Research [Sydney], The University of Sydney, Vall d'Hebron University Hospital [Barcelona], ProAR - FMB, Federal University of Bahia School of Medicine, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), University Hospitals Leuven [Leuven], Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Vilnius University [Vilnius], Clínica de Alergia- Asma y Pediatría, Hospital Medica Sur, Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris] (IP), Medical University of Warsaw - Poland, Department of Pulmonology, Manisa Celal Bayar University, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Aix Marseille Université (AMU), Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), iQ4U consultants Ltd, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Department of Respiratory Medicine and Allergy, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, CHU Montpellier, Laboratoire National Henri Becquerel (LNHB), Département Métrologie Instrumentation & Information (DM2I), Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Département d'instrumentation Numérique (DIN (CEA-LIST)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Région Languedoc-Roussillon-Midi-Pyrénées, University of South Florida [Tampa] (USF), Chinese academy of sciences Sanya, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Department of Paediatrics, UCB Pharma, Colombes, CHU Strasbourg, Università degli Studi di Salerno = University of Salerno (UNISA), Hôpital Foch [Suresnes], Service de pneumologie [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Informatique, Image, Intelligence Artificielle (I3A), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-IMT - MINES ALES (IMT - MINES ALES), Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Center for Turbulence Research [Stanford] (CTR), Stanford University, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Biomax Informatics AG, 'Federico II' University of Naples Medical School, Pneumology Department, Marius Nasta Institute of Pneumology, Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Johns Hopkins University School of Medicine [Baltimore], CARSAT-LR, Montpellier, Dept. of Electronic Engineering, Chubu University, Institute for Solid State Physics, The University of Tokyo (UTokyo), Respiratory Medicine, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, University of Cyprus [Nicosia] (UCY), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Department of Computer Science [Haifa], University of Haifa [Haifa], University of Edinburgh, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Réseau National de Surveillance Aérobiologique (RNSA), CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, University of Turku, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), ASA (Advanced Solution Accelerator) (Data management : Développement Back-Office, hébergement…), 34830 Jacou, Consiglio nazionale delle ricerche, Instituto di fisiologia clinica, McMaster University [Hamilton, Ontario], Department of Molecular Medicine and Surgery, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), University Hospital of Cologne [Cologne], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), ISGlobal, Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Porto, Portugal, KYomed INNOV, Montpellier, France, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, MACVIA-France, Montpellier, France, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, Euforea, Brussels, Belgium, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Clinic of Chest diseases and Allergology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino & Mauriziano Hospital, Torino, Italy, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, Pasteur Institute, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Department of General ORL, H&NS, Medical University of Graz, Graz, Austria, Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, University Hospital, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität, Marburg, Germany, Universidade do Porto, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Pasteur [Paris], University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Università degli Studi di Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Arts et Métiers (ENSAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, University of Helsinki, Service d'Allergologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Cyprus [Nicosia], Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Bedard, A., Anto, J. M., Fonseca, J. A., Arnavielhe, S., Bachert, C., Bedbrook, A., Bindslev-Jensen, C., Bosnic-Anticevich, S., Cardona, V., Cruz, A. A., Fokkens, W. J., Garcia-Aymerich, J., Hellings, P. W., Ivancevich, J. C., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linnemann, D., Melen, E., Monti, R., Mosges, R., Mullol, J., Papadopoulos, N. G., Pham-Thi, N., Samolinski, B., Tomazic, P. V., Toppila-Salmi, S., Ventura, M. T., Yorgancioglu, A., Bousquet, J., Pfaar, O., Basagana, X., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Aliberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Bateman, E. D., Bedolla-Barajas, M., Bewick, M., Beghe, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Bialoszewski, A. Z., Bieber, T., Bialek, S., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabanas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillaud, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Constantinidis, J., Correia de Sousa, J., Cortes-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Custovic, A., Czarlewski, W., Dahlen, S. E., D'Amato, G., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fatima Emerson, M., De Feo, G., De Vries, G., De Martino, B., Motta Rubini, N. P., Deleanu, D., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Galvez-Romero, J. L., Gamkrelidze, A., Garcia-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioglu, B., Genova, S., Christoff, G., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gomez-Vera, J., Gonzalez Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzman, M. A., Haahtela, T., Hajjam, J., Hernandez, L., Hourihane, J. O. '. B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ispayeva, Z., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Just, J., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M. L., Kuitunen, M., Kull, I., Kupczyk, M., Krzych-Falta, E., Lacwik, P., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenco, O., Luna-Pech, J. A., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Meco, C., Medina-Avalos, M. A., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mota-Pinto, A., Moura Santo, P., Munter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Scholl, I., Palkonen, S., Panzner, P., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pepin, J. L., Pereira, A. M., Persico, M., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Manas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimaki, J., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Sarquis Serpa, F., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Sole, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyrica, J. N., Thibaudon, M., To, T., Todo-Bom, A., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hage, M., Vandenplas, O., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, G., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zhanat, I., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Universidade do Porto [Porto], Kyomed, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Universitat Pompeu Fabra [Barcelona], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Dermatology [Graz, Austria], Medical University Graz, University of Zürich [Zürich] (UZH), National Institute for Nuclear Physics (INFN), Institut Jean Lamour (IJL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Clermont Université-Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Recherche Agronomique (INRA), University of South Florida (USF), University of Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey, Institut Mines-Télécom [Paris] (IMT), Center for Turbulence Research (CTR), Stanford University [Stanford], Service d'allergologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), The University of Tokyo, Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), RNSA, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bedard A., Anto J.M., Fonseca J.A., Arnavielhe S., Bachert C., Bedbrook A., Bindslev-Jensen C., Bosnic-Anticevich S., Cardona V., Cruz A.A., Fokkens W.J., Garcia-Aymerich J., Hellings P.W., Ivancevich J.C., Klimek L., Kuna P., Kvedariene V., Larenas-Linnemann D., Melen E., Monti R., Mosges R., Mullol J., Papadopoulos N.G., Pham-Thi N., Samolinski B., Tomazic P.V., Toppila-Salmi S., Ventura M.T., Yorgancioglu A., Bousquet J., Pfaar O., Basagana X., Aberer W., Agache I., Akdis C.A., Akdis M., Aliberti M.R., Almeida R., Amat F., Angles R., Annesi-Maesano I., Ansotegui I.J., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Bateman E.D., Bedolla-Barajas M., Bewick M., Beghe B., Bel E.H., Bergmann K.C., Bennoor K.S., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bosse I., Bouchard J., Boulet L.P., Bourret R., Bousquet P.J., Braido F., Briedis V., Brightling C.E., Brozek J., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillaud D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Canonica G.W., Carlsen K.H., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Casale T., Castellano G., Cecchi L., Cepeda A.M., Chavannes N.H., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Constantinidis J., Correia de Sousa J., Cortes-Grimaldo R.M., Corti F., Costa E., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Czarlewski W., Dahlen S.E., D'Amato G., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., De Carlo G., Dedeu T., de Fatima Emerson M., De Feo G., De Vries G., De Martino B., Motta Rubini N.P., Deleanu D., Denburg J.A., Devillier P., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Dykewicz M.S., El-Gamal Y., Eklund P., Eller E., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Fontaine J.F., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., Christoff G., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Guzman M.A., Haahtela T., Hajjam J., Hernandez L., Hourihane J.O.'.B., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Illario M., Ispayeva Z., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Just J., Jutel M., Kaidashev I., Kalayci O., Kalyoncu A.F., Karjalainen J., Kardas P., Keil T., Keith P.K., Khaitov M., Khaltaev N., Kleine-Tebbe J., Kowalski M.L., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Laune D., Lauri D., Lavrut J., Le L.T.T., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Lourenco O., Luna-Pech J.A., Magnan A., Mahboub B., Maier D., Mair A., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Meco C., Medina-Avalos M.A., Melo-Gomes E., Meltzer E.O., Menditto E., Mercier J., Miculinic N., Mihaltan F., Milenkovic B., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Mora Bogado D., Morais-Almeida M., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Murray R., Naclerio R., Nadif R., Nalin M., Napoli L., Namazova-Baranova L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Novellino E., Nyembue T.D., O'Hehir R.E., Odzhakova C., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Palkonen S., Panzner P., Park H.S., Papi A., Passalacqua G., Paulino E., Pawankar R., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Plavec D., Pohl W., Popov T.A., Portejoie F., Potter P., Pozzi A.C., Price D., Prokopakis E.P., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Rajabian-Soderlund R., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Rottem M., Ryan D., Sagara H., Salimaki J., Sanchez-Borges M., Sastre-Dominguez J., Scadding G.K., Schunemann H.J., Scichilone N., Schmid-Grendelmeier P., Sarquis Serpa F., Shamai S., Sheikh A., Sierra M., Simons F.E.R., Siroux V., Sisul J.C., Skrindo I., Sole D., Somekh D., Sondermann M., Sooronbaev T., Sova M., Sorensen M., Sorlini M., Spranger O., Stellato C., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., To T., Todo-Bom A., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., Valero A., Valiulis A., Valovirta E., van Eerd M., van Ganse E., van Hage M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi G., Vicheva D., Vontetsianos T., Wagenmann M., Walker S., Wallace D., Wang D.Y., Waserman S., Werfel T., Westman M., Wickman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zhang L., Zhong N., Zernotti M.E., Zhanat I., Zidarn M., Zuberbier T., Zubrinich C., and Zurkuhlen A.
- Subjects
0301 basic medicine ,SYMPTOMS ,Smart phone ,Allergy ,Escala visual analógica ,INNOVATION ,[SDV]Life Sciences [q-bio] ,Medical and Health Sciences ,Correlation ,visual analogue scale ,0302 clinical medicine ,Quality of life ,Visual analogue scale ,QUALITY-OF-LIFE ,Màscares ,Immunology and Allergy ,score ,Nose ,Rinitis ,Rhinitis ,PRODUCTIVITY COSTS ,asthma ,MASK ,rhinitis ,Score ,Explained variation ,Response Variability ,Mobile Applications ,ALLERGIC RHINITIS ,rhiniti ,medicine.anatomical_structure ,TRIALS ,Rinite ,1107 Immunology ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Smartphone ,medicine.medical_specialty ,MASK study group ,Immunology ,MACVIA-ARIA ,03 medical and health sciences ,Allergic ,medicine ,Humans ,TECHNOLOGY ,IMMUNOTHERAPY ,Asma ,Asthma ,business.industry ,Rhinitis, Allergic ,medicine.disease ,RHINOCONJUNCTIVITIS ,030104 developmental biology ,030228 respiratory system ,3121 General medicine, internal medicine and other clinical medicine ,Physical therapy ,Clinical Medicine ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2020
5. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study
- Author
-
Samreth, D, Arnavielhe, S, Ingenrieth, F, Bedbrook, A, Onorato, G L, Murray, R, Almeida, R, Mizani, M A, Fonseca, J, Costa, E, Malva, J, Morais-Almeida, M, Pereira, A M, Todo-Bom, A, Menditto, E, Stellato, C, Ventura, M T, Larenas-Linnemann, D, Fuentes-Pérez, J-M, Huerta-Villalobos, Y R, Cruz, A A, Stelmach, R, da Silva, J, Emuzyte, R, Kvedariene, V, Valiulis, A, Annesi-Maesano, I, Bosse, I, Demoly, P, Devillier, P, Fontaine, J F, Kuna, P, Samolinski, B, Klimek, L, Mösges, R, Pfaar, O, Shamai, S, Bewick, M, Ryan, D, Sheikh, A, Anto, J M, Cardona, V, Mullol, J, Valero, A, Chavannes, N H, Fokkens, W J, Reitsma, S, Roller-Wirnsberger, R E, Tomazic, P V, Haahtela, T, Toppila-Salmi, S, Valovirta, E, Makris, M, Papadopoulos, N G, Prokopakis, E P, Psarros, F, Gemicioğlu, B, Yorgancioglu, A, Bindslev-Jensen, C, Eller, E, Kull, I, Wickman, M, Bachert, C, Hellings, P W, Pugin, B, Bosnic-Anticevich, S, O'Hehir, R E, Kolek, V, Sova, M, Wehner, K, De Vries, G, van Eerd, M, Laune, D, Wittmann, J, Bousquet, J, Poncelet, P, Agache, I, Angles, R, Anto, Jm, Asayag, E, Bacci, E, Baiardini, I, Baroni, I, Barreto, Ba, Basagana, X, Bedolla-Barajas, M, Bergmann, Kc, Bertorello, L, Bialek, S, Bieber, T, Bjermer, L, Blua, A, Bochenska Marciniak, M, Bogus-Buczynska, I, Bouchard, J, Bourret, R, Briedis, V, Bucca, C, Buonaiuto, R, Burguete Cabanas MT, Caiazza, D, Caillot, D, Caimmi, D, Camargos, P, Canfora, G, Carriazo, Am, Cartier, C, Carla Carvalho Coelho, A, Castellano, G, Cecchi, L, Chavannes, Nh, Ciaravolo, Mm, Cingi, C, Ciceran, A, Colas, L, Colgan, E, Coll, J, Conforti, D, Correia da Sousa, J, Cortés-Grimaldo, Rm, Corti, F, Costa, Dj, Costa Dominguez MC, Courbis, Al, Cruz, Aa, Custovic, A, Czarlewski, W, Dario, C, Dauvilliers, Y, De Carlo, G, De Blay, F, Dedeu, T, de Fátima Emerson, M, De Feo, G, Garcia Cruz MH, De Martino, B, de Paula Motta Rubini, N, Di Capua Ercolano, S, Di Carluccio, N, Dray, G, Dubakiene, R, Espinoza-Contreras, Jm, Estrada-Cardona, A, Farrell, J, Farsi, A, Ferreira de Mello, J Jr, Ferrero, J, Fokkens, Wj, Fontaine, Jf, Forti, S, Garcia-Aymerich, J, Gálvez-Romero, Jl, García-Cobas, Ci, Gerth van Wijk, R, Guidacci, M, Gómez-Vera, J, Guldemond, Na, Gutter, Z, Hajjam, J, Hellings, Pw, Hernández, L, Illario, M, Ivancevich, Jc, Jares, E, Joos, G, Just, J, Kalayci, O, Kalyoncu, Af, Karjalainen, J, Keil, T, Khaltaev, N, Kowalski, Ml, Krzych-Fałta, E, Kupczyk, M, Lacwik, P, Lauri, D, Lavrut, J, Lessa, Ma, Levato, G, Lewis, L, Lieten, I, Lipiec, A, Louis, R, Luna-Pech, Ja, Maciej, K, Magnan, A, Maspero, Jf, Mathieu-Dupas, E, Matos, Al, Mayora, O, Medina-Ávalos, Ma, Melen, E, Millot-Keurinck, J, Mizani, Ma, Moda, G, Morato-Castro, Ff, Moura Santo, P, Mota-Pinto, A, Murraro, A, Nalin, M, Noguès, M, Novellino, E, Napoli, L, Neffen, H, O'Hehir, Re, Onorato, Gl, Palkonen, S, Papadopoulos, Ng, Passalacqua, G, Pépin, Jl, Pereira, Am, Persico, M, Picard, R, Portejoie, F, Pozzi, Ac, Price, D, Prokopakis, Ep, Puy, R, Przemecka-Green, M, Raciborski, F, Rajabian-Soderlund, R, Ribeirinho, I, Rimmer, J, Rizzo, Ja, Rizzo, Mc, Robalo-Cordeiro, C, Rodo, X, Rodrigues Valle, S, Rodríguez-González, M, Rolla, G, Roller-Wirnsberger, Re, Romano, A, Romano, M, Rosario, N, Salimäki, J, Sierra, M, Simons, Fer, Solé, D, Sorlini, M, Spranger, O, A C, Stellato, Strozek, J, Stukas, R, Sutherland, M, Szylling, A, Tebyriçá, Jn, Thibaudon, M, Tibaldi, V, Tomazic, P, Trama, U, Triggiani, M, Urrutia-Pereira, M, Vandenplas, O, Vasankari, T, Vatrella, A, Ventura, Mt, Verissimo, Mt, Viart, F, Williams, S, Wagenmann, M, Westman, M, Wroczynski, P, Zernotti, E, Zurbierber, T, Zubrinich, C, Zurkuhlen, A., Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade de Lisboa (ULISBOA), Universitat Politècnica de València (UPV), University of Coimbra [Portugal] (UC), 'Federico II' University of Naples Medical School, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Universidade Federal de Santa Catarina = Federal University of Santa Catarina [Florianópolis] (UFSC), Vilnius University [Vilnius], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Hôpital Foch [Suresnes], Erosion torrentielle neige et avalanches (UR ETGR (ETNA)), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Heidelberg University, University Hospital of Cologne [Cologne], Department of Computer Science [Haifa], University of Haifa [Haifa], University of Edinburgh, Vall d'Hebron University Hospital [Barcelona], University of Barcelona, Karl-Franzens-Universität [Graz, Autriche], University of Helsinki, University of Turku, Department of Cardiovascular Science [Sheffield], University of Sheffield [Sheffield], The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Ghent University Hospital, University Hospitals Leuven [Leuven], The University of Sydney, Monash University [Melbourne], Institut de Recherche en Infectiologie de Montpellier (IRIM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), ADVanced Analytics for data SciencE (ADVANSE), Laboratoire d'Informatique de Robotique et de Microélectronique de Montpellier (LIRMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Ear, Nose and Throat, AII - Inflammatory diseases, Department of Dermatology, Allergology and Venereology, Clinicum, Sanna Katriina Toppila-Salmi / Principal Investigator, HUS Inflammation Center, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Universidad Politécnica de Valencia, Federal University of Santa Catarina (UFSC), University of Graz, Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France and Euforea, Brussels, Belgium, Faculty of Medicine, Transylvania University, Brasov, Romania, Center for Health Technology and Services Research-CINTESIS, Faculdade de Medicina, Universidade do Porto, and Medina, Lda Porto, Portugal, Innovación y nuevas tecnologías, Salud Sector sanitario de Barbastro, Barbastro, Spain, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Kyomed, Montpellier, France, Argentine Society of Allergy and Immunopathology, Buenos Aires, Argentina, Regione Liguria, Genoa, Italy, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Department of ENT diseases, Karolinska University Hospital, Stockholm, Sweden, Telbios SRL, Milan, Italy, Universidade do Estado do Pará, Belem, Brazil, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, iQ4U Consultants Ltd, London, United Kingdom, Dept of Biochemistry and Clinical Chemistry-Dpt of Postgraduate Education, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Poland, Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Argentine Association of Respiratory Medicine, Buenos Aires, Argentina, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Associate professor of clinical medecine, Laval's University, Quebec city, Head of medecine department, Hôpital de la Malbaie, Quebec, Canada, Centre Hospitalier Valenciennes, France, Head of Department of Clinical Pharmacy of Lithuanian University of Clinical Sciences, Kaunas, Lithuania, Chief of the University Pneumology Unit-AOU Molinette, Hospital City of Health and Science of Torino, Italy, Municipality PharmacySarno, Italy, Nuove Leon, Monterey, Mexico, Pharmacist, Municipality Pharmacy, Mercato Sam Severino, Italy, Service de pneumologie, CHU et université d'Auvergne, Clermont-Ferrand, France, Department of Respiratory Diseases, Montpellier University Hospital, France, Federal University of Minas Gerais, Medical School, Department of Pediatrics, Belo Horizonte, Brazil, Mayor of Sarno and President of Salerno Province, Director, Anesthesiology Service, Sarno 'Martiri del Villa Malta' Hospital, Italy, S Allergologia, S Medicina Interna, Hospital Vall d'Hebron, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, ASA-Advanced Solutions Accelerator, Clapiers, France, Universidade Federal da Bahia, Salvador, Brazil, Celentano pharmacy, Massa Lubrense, Italy, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Specialist social worker, Sorrento, Italy, Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey, Argentine Federation of Otorhinolaryngology Societies, Buenos Aires, Argentina, University of Nantes, Service de Pneumologie, UMR INSERM, UMR 1087 and CNR 6291, l'institut du thorax, Nantes, France, LANUA International Healthcare Consultancy, United Kingdom, Fondazione Bruno Kessler (FBK), Trento, Italy, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, Guadalarara, Mexico, FIMMG (Federazione Italiana Medici di Medicina Generale), Milan, Italy, General Practice, Nîmes, France, Dominguez C. Ciutad Mexico, Mexico, IMT Mines-Alès, Univ. Montpellier, Alès, France, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Brazil, Department of Pediatric, Imperial College London, United Kingdom, Medical Consulting Czarlewski, Levallois, France, Azienda Provinciale per i Servizi Sanitari di Trento (APSS-Trento), Italy, Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São, Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianopolis-SC, Brazil, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac MontpellierInserm U1061, France, EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium, Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France, AQuAS, Barcelna, Spain & EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Policlínica Geral do Rio de Janeiro, Rio de Janeiro, Brazil, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Allergy Clinic, National Institute of Respiratory Diseases, Mexico City, Mexico, Social workers oordinator, Sorrento, Italy, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Peercode BV, Geldermalsen, Netherlands, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, University of Aguascalientes, Chihuaha, Mexico, Playa del Carmen, Mexico, JUniversidade de São Paulo, São Paulo, Brazil, Andalusian Agency for Healthcare Quality, Seville, Spain, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Reims, France, Regional hospital of ISSSTE, Puebla, Mexico, Department of Pulmonary Diseases, Istanbul University, Cerrahpasa Faculty of Medicine, Turkey, Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam, Netherlands, Hospital de Base de Brasilia, Brazil, Allergy Clinic, Hospital Regional del ISSSTE ‘Lic. López Mateos’, Mexico City, Mexico, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, University Hospital Olomouc – National eHealth Centre, Czech Republic, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Centich: centre d’expertise national des technologies de l’information et de la communication pour l’autonomie, Gérontopôle autonomie longévité des Pays de la Loire, Conseil régional des Pays de la Loire, Centre d’expertise Partenariat Européen d’Innovation pour un vieillissement actif et en bonne santé, Nantes, France, Dept of Otorhinolaryngology, Univ Hospitals Leuven, Belgium, and Academic Medical Center, Univ of Amsterdam, The Netherlands and Euforea, Brussels, Belgium, Ensenada, Mexico, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET) Naples, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, President, Libra Foundation, Buenos Aires, Argentina, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Allergology department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Sorbonne Université, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Hacettepe University, School of Medicine, Department of Chest Diseases, Immunology and Allergy Division, Ankara, Turkey, Allergy Centre, Tampere University Hospital, Tampere, Finland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Berlin, Germany, GARD Chairman, Geneva, Switzerland, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, and HARC, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Poland, Center of Excellence in Asthma and Allergy, Hospital Médica Sur, México City, Mexico, Presidente CMMC, Milano, Italy, Head of the Allergy Department of Pedro de Elizalde Children's Hospital, Buenos Aires, Argentina, Faculdade de Medicina da, Universidade Federal da Bahia, Salvador de Bahia, Brazil, Milano, Italy, Promotor B3 Action GRoup EIP on AHA and Senior Fellow, International Foundation for Integreted Care, Aberystwyth, United Kingdom, Tech Life Valley, Diepenbeek, Belgium, Department of Pulmonary Medicine, CHU Sart-Tilman, University of Liege, GIGA I3 research group, Liege, Belgium, University of Guadalajara, Guadalara, Mexico, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Portugal, University of Southeast Bahia, Brazil, Veracruz, Mexico, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, CIRFF, Federico II University, Naples, Italy, Caisse d'assurance retraite et de la santé au travail du Languedoc-Roussillon (CARSAT-LR), Montpellier, France, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Regione Piemonte, Torino, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Universidade de São Paulo, São Paulo, Brazil, Federal University of Bahia, Brazil, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, CRI-Clinical Research International-Ltd., Hamburg, Germany, General Pathology Institute, Faculty of Medicine, University of Coimbra, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Portugal, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, Director, Medical Communications Consultant, MedScript Ltd, Dundalk, Co Louth, Ireland, Director of Department of Pharmacy of University of Naples Federico II, Naples, Italy, Director, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Director of Center of Allergy, Immunology and Respiratory Diseases, Argentina, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, M13 9WL, United Kingdom, Allergy and Respiratory Diseases, Ospedale Policlino San Martino-University of Genoa, Italy, Université Grenoble Alpes, Laboratoire HP2, Grenoble, INSERM, U1042 and CHU de Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Portugal, municipality area n33, Sorrento, Italy, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Conseil Général de l'Economie Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France, LIRMM, Montpellier, France, Vice-Presidente of IML, Milano, Italy, Observational and Pragmatic Research Institute, Optimum Patient Care, Academic Centre of Primary Care, University of Aberdeen, Cambridge, United Kingdom, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Centre of Pneumology, Coimbra University Hospital, Portugal, Climate and Health Program, ISGlobal and ICREA, Barcelona, Spain, Pediatric Allergy and Clinical Immunology, Hospital Angeles Pedregal, Mexico, Allergy Unit, Presidio Columbus, Catholic University of Sacred Heart, IRCCS Oasi Maria SS, Troina, Italy, Department of Pediatrics & Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada, Universidade Federal de São Paulo, São Paulo, Brazil, IML (Lombardy Medical Initiative), Bergamo, Italy, Global Allergy and Asthma Platform GAAPP, Altgasse 8-10, Vienna, 1130, Austria, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Public Health Institute of Vilnius University, Vilnius, Lithuania, Alfred Hospital, Melbourne, VIC, Australia, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Portugal, Department of ENT, Medical University of Graz, Austria, Campania Region, Division on Pharmacy and devices policy, Naples, Italy, Universidade Federal dos Pampas, Uruguaiana, Brazil, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Spain, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, Turku, Finland, Vilnius University Institute of Clinical Medicine, Clinic of Children's Diseases, and Institute of Health Sciences, Department of Public Health, Vilnius, Lithuania, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, FILHA, Finnish Lung Association, Helsinki, Finland, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Dept of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Germany, Department of Physical Pharmacy and Bioanalysis, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Warsaw, Poland, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Universidad Católica de Córdoba, Córdoba, Argentina, Gesundheitsregion KölnBonn-HRCB Projekt GmbH, Kohln, Germany, Montpellier, France, Selbstregulierung Informationswirtschaft eV, Berlin, Germany, MedScript Ltd, Dundalk, Co Louth, Ireland, and Medina, Lda, Porto, Portugal, Asthma UK Centre for Applied Research, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy, Ageing of University of Porto (Porto4Ageing), Porto, Portugal, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Ageing@Coimbra EIP-AHA Reference Site, University of Coimbra, Coimbra, Portugal, Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Porto, Portugal, Imunoalergologia Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Mexico City, Mexico, ProAR – Nucleo de Excelencia em Asma, Brasil and WHO GARD Planning Group, Federal University of Bahia, Salvador, Brazil, Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São, Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianopolis, SC, Brazil, Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Clinic of Children’s Diseases, and Institute of Health Sciences, Department of Public Health, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, Medical School Saint Antoine, INSERM and Sorbonne Université, Paris, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Samolinski. Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International Ltd, Hamburg, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany, Woodbrook Medical Centre, Loughborough, United Kingdom, Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Edinburgh, United Kingdom, S Allergologia, S Medicina Interna, Hospital Vall d’Hebron, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Department of ENT, Medical University of Graz, Graz, Austria, Division of Infection, Immunity 1 Respiratory Medicine, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece, Allergy Department, Athens Naval Hospital, Athens, Greece, Department of Pulmonary Diseases, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, Department of Pulmonary Diseases, Faculty of Medicine, Turkey and GARD Executive Committee, Celal Bayar University, Manisa, Turkey, Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Department of Otorhinolaryngology, Univ Hospitals Leuven, Leuven, Belgium, Academic Medical Center, Univ of Amsterdam, Amsterdam, Netherlands, Euforea, Brussels, Belgium, Department of Immunology, Monash University, Melbourne, VIC, Australia, Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic, Fachbereich Biologie, Technische Universität, Darmstadt, Germany, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Bousquet, J., Agache, I., Almeida, R., Angles, R., Annesi-Maesano, I., Anto, J. M., Arnavielhe, S., Asayag, E., Bacci, E., Bachert, C., Baiardini, I., Baroni, I., Barreto, B. A., Basagana, X., Bedbrook, A., Bedolla-Barajas, M., Bergmann, K. C., Bertorello, L., Bewick, M., Bialek, S., Bieber, T., Bindslev-Jensen, C., Bjermer, L., Blua, A., Marciniak, M. B., Bogus-Buczynska, I., Bosnic-Anticevich, S., Bosse, I., Bouchard, J., Bourret, R., Briedis, V., Bucca, C., Buonaiuto, R., Cabanas, M. T. B., Caiazza, D., Caillot, D., Caimmi, D., Camargos, P., Canfora, G., Cardona, V., Carriazo, A. M., Cartier, C., Coelho, A. C. C., Castellano, G., Cecchi, L., Chavannes, N. H., Ciaravolo, M. M., Cingi, C., Ciceran, A., Colas, L., Colgan, E., Coll, J., Conforti, D., Sousa, J. C. D., Cortes-Grimaldo, R. M., Corti, F., Costa, D. J., Dominguez, M. C. C., Courbis, A. L., Cruz, A. A., Custovic, A., Czarlewski, W., Dario, C., Silva, J. D., Dauvilliers, Y., Carlo, G. D., Blay, F. D., Dedeu, T., Emerson, M. F., Feo, G. D., Cruz, M. H. G., Martino, B. D., Demoly, P., Rubini, N. P. M., Devillier, P., De Vries, G., Ercolano, S. D. C., Di Carluccio, N., Dray, G., Dubakiene, R., Eller, E., Emuzyte, R., Espinoza-Contreras, J. M., Estrada-Cardona, A., Farrell, J., Farsi, A., de Mello, J. F., Ferrero, J., Fokkens, W. J., Fonseca, J., Fontaine, J. F., Forti, S., Garcia-Aymerich, J., Galvez-Romero, J. L., Garcia-Cobas, C. I., Gemicioglu, B., van Wijk, R. G., Guidacci, M., Gomez-Vera, J., Guldemond, N. A., Gutter, Z., Haahtela, T., Hajjam, J., Hellings, P. W., Hernandez, L., Illario, M., Ivancevich, J. C., Jares, E., Joos, G., Just, J., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Keil, T., Khaltaev, N., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Kolek, V., Krzych-Falta, E., Kupczyk, M., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Lessa, M. A., Levato, G., Lewis, L., Lieten, I., Lipiec, A., Louis, R., Luna-Pech, J. A., Maciej, K., Magnan, A., Malva, J., Maspero, J. F., Mathieu-Dupas, E., Matos, A. L., Mayora, O., Medina-avalos, M. A., Melen, E., Menditto, E., Millot-Keurinck, J., Mizani, M. A., Moda, G., Morais-Almeida, M., Morato-Castro, F. F., Santo, P. M., Mosges, R., Mota-Pinto, A., Mullol, J., Murraro, A., Murray, R., Nalin, M., Nogues, M., Novellino, E., Napoli, L., Neffen, H., O'Hehir, R. E., Onorato, G. L., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pepin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Picard, R., Poncelet, P., Portejoie, F., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Przemecka-Green, M., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodo, X., Valle, S. R., Rodriguez-Gonzalez, M., Rolla, G., Roller-Wirnsberger, R. E., Romano, A., Romano, M., Rosario, N., Ryan, D., Salimaki, J., Samolinski, B., Samreth, D., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Sole, D., Sorlini, M., Spranger, O., Stellato, C., Stelmach, A. R., Strozek, J., Stukas, R., Sutherland, M., Szylling, A., Tebyrica, J. N., Thibaudon, M., Tibaldi, V., Todo-Bom, A., Toppila-Salmi, S., Tomazic, P., Trama, U., Triggiani, M., Urrutia-Pereira, M., Valero, A., Valovirta, E., Valiulis, A., Vandenplas, O., van Eerd, M., Vasankari, T., Vatrella, A., Ventura, M. T., Verissimo, M. T., Viart, F., Williams, S., Wagenmann, M., Westman, M., Wickman, M., Wroczynski, P., Yorgancioglu, A., Zernotti, E., Zurbierber, T., Zubrinich, C., Zurkuhlen, A., Ingenrieth, F., Costa, E., Fuentes-Perez, J. -M., Huerta-Villalobos, Y. R., da Silva, J., Tomazic, P. V., Makris, M., Psarros, F., Sova, M., Wehner, K., Wittmann, J., UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Internal Medicine, Universidade do Minho, and Göğüs Hastalıkları
- Subjects
0301 basic medicine ,Lydia Becker Institute ,Respiratory Medicine and Allergy ,Anonymization ,k-anonymity ,Medicina Clínica [Ciências Médicas] ,Health data ,0302 clinical medicine ,610 Medical sciences Medicine ,Medicine and Health Sciences ,Medicine ,Immunology and Allergy ,European commission ,HEALTH DATA ,Rinitis ,Lungmedicin och allergi ,Original Research ,Rhinitis ,App ,Asthma ,MASK ,Immunology ,Pulmonary and Respiratory Medicine ,Data anonymization ,Communication Systems ,Kommunikationssystem ,lcsh:Immunologic diseases. Allergy ,MASK study group ,Internet privacy ,K-ANONYMITY ,Anonymization, App, Asthma, MASK, Rhinitis ,03 medical and health sciences ,ResearchInstitutes_Networks_Beacons/lydia_becker_institute_of_immunology_and_inflammation ,PROTECTING PRIVACY ,TECHNOLOGY ,Asma ,Ciências Médicas::Medicina Clínica ,business.industry ,1103 Clinical Sciences ,Geolocation ,[MATH.MATH-LO]Mathematics [math]/Logic [math.LO] ,030104 developmental biology ,030228 respiratory system ,3121 General medicine, internal medicine and other clinical medicine ,Key (cryptography) ,ComputingMilieux_COMPUTERSANDSOCIETY ,Noise (video) ,business ,lcsh:RC581-607 - Abstract
Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission's Article 29 Working Party stated that geolocation information is personal data.To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method., Background Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission’s Article 29 Working Party stated that geolocation information is personal data. To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method. Methods Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization). Results Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58.5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users’ life privacy. Discussion k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases., AMC -Istanbul Üniversitesi(undefined), info:eu-repo/semantics/publishedVersion
- Published
- 2018
6. ARIA Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
- Author
-
Bousquet, J, Hellings, Pw, Agache, I, Amat, F, Annesi-Maesano, I, Ansotegui, Ij, Anto, Jm, Bachert, C, Bateman, Ed, Bedbrook, A, Bennoor, K, Bewick, M, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bosse, I, Brozek, J, Brussino, L, Canonica, Gw, Cardona, V, Casale, T, Cepeda Sarabia AM, Chavannes, Nh, Cecchi, L, Correia de Sousa, J, Costa, E, Cruz, Aa, Czarlewski, W, De Carlo, G, De Feo, G, Demoly, P, Devillier, P, Dykewicz, Ms, El-Gamal, Y, Eller, E, Fonseca, Ja, Fontaine, Jf, Fokkens, Wj, Guzmán, Ma, Haahtela, T, Illario, M, Ivancevich, Jc, Just, J, Kaidashev, I, Khaitov, M, Kalayci, O, Keil, T, Klimek, L, Kowalski, Ml, Kuna, P, Kvedariene, V, Larenas-Linnemann, D, Laune, D, Le, Lt, Carlsen, Kh, Lourenço, O, Mahboub, B, Mair, A, Menditto, E, Milenkovic, B, Morais-Almeida, M, Mösges, R, Mullol, J, Murray, R, Naclerio, R, Namazova-Baranova, L, Novellino, E, O'Hehir, Re, Ohta, K, Okamoto, Y, Okubo, K, Onorato, Gl, Palkonen, S, Panzner, P, Papadopoulos, Ng, Park, Hs, Paulino, E, Pawankar, R, Pfaar, O, Plavec, D, Popov, Ta, Potter, P, Prokopakis, Ep, Rottem, M, Ryan, D, Salimäki, J, Samolinski, B, Sanchez-Borges, M, Schunemann, Hj, Sheikh, A, Sisul, Jc, Rajabian-Söderlund, R, Sooronbaev, T, Stellato, C, To, T, Todo-Bom, Am, Tomazic, Pv, Toppila-Salmi, S, Valero, A, Valiulis, A, Valovirta, E, Ventura, Mt, Wagenmann, M, Wang, Y, Wallace, D, Waserman, S, Wickman, M, Yorgancioglu, A, Zhang, L, Zhong, N, Zidarn, M, Zuberbier, T, Vatrella, Alessandro, and Triggiani, Massimo
- Subjects
ARIA ,rhinitis ,Change management ,asthma - Published
- 2018
7. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA)
- Author
-
Bousquet, J, Agache, I, Aliberti, MR, Angles, R, Annesi-Maesano, I, Anto, JM, Arnavielhe, S, Asayag, E, Bacci, E, Bedbrook, A, Bachert, C, Valero, A, Valovirta, E, Valiulis, A, Van Eerd, M, Vasankari, T, Vatrella, A, Ventura, MT, Verissimo, MT, Viart, F, Bindslev-Jensen, C, Khaltaev, N, Williams, S, Wagenmann, M, Wanscher, C, Westman, M, Wickman, M, Young, I, Yorgancioglu, A, Zernotti, E, Zurbierber, T, Zurkuhlen, A, Klimek, L, Blua, A, De Oliviera, B, Senn, A, Bochenska Marciniak, M, Bogus-Buczynska, I, Bosnic-Anticevich, S, Bosse, I, Bourret, R, Bucca, C, Buonaiuto, R, Kritikos, V, Caiazza, D, Caillot, D, Caimmi, DP, Camargos, P, Canfora, G, Cardona, V, Carriazo, AM, Cartier, C, Castellano, G, Chavannes, NH, Kull, I, Ciaravolo, MM, Cingi, C, Ciceran, A, Colas, L, Colgan, E, Coll, J, Conforti, D, De Sousa, JC, Cortés-Grimaldo, RM, Corti, F, Kuna, P, Costa, E, Courbis, AL, Cousein, E, Cruz, AA, Custovic, A, Cvetkovski, B, Dario, C, Da Silva, M, Dauvilliers, Y, De Blay, F, Kvedariene, V, Dedeu, T, De Feo, G, De Martino, B, Demoly, P, De Vries, G, Di Capua Ercolano, S, Di Carluccio, N, Doulapsi, M, Dray, G, Dubakiene, R, Kolek, V, Eller, E, Emuzyte, R, Espinoza-Contreras, JM, Estrada-Cardona, A, Farrell, J, Ferrero, J, Fokkens, WJ, Fonseca, J, Fontaine, JF, Forti, S, Krzych-Fałta, E, Gálvez-Romero, JL, García-Cobas, CI, Cruz, MHG, Gemicioğlu, B, Van Wijk, RG, Guidacci, M, Gómez-Vera, J, Guldemond, NA, Gutter, Z, Haahtela, T, Kupczyk, M, Hajjam, J, Hellings, PW, Hernández-Velázquez, L, Illario, M, Ivancevich, JC, Jares, E, Joos, G, Just, J, Kalayci, O, Kalyoncu, AF, Lacwik, P, Karjalainen, J, Keil, T, Baroni, I, Larenas-Linnemann, D, Laune, D, Lauri, D, Lavrut, J, Lessa, M, Levato, G, Lewis, L, Lieten, I, Lipiec, A, Louis, R, Barreto, BA, Luna-Pech, JA, Magnan, A, Malva, J, Maspero, JF, Matta-Campos, JJ, Mayora, O, Medina-Ávalos, MA, Melén, E, Menditto, E, Millot-Keurinck, J, Bedolla-Barajas, M, Moda, G, Morais-Almeida, M, Mösges, R, Mota-Pinto, A, Mullol, J, Muraro, A, Murray, R, Noguès, M, Nalin, M, Napoli, L, Bergmann, KC, Neffen, H, O'Hehir, RE, Onorato, G, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pépin, JL, Pereira, AM, Persico, M, Pfaar, O, Bertorello, L, Pozzi, AC, Prokopakis, E, Raciborski, F, Rimmer, J, Rizzo, JA, Robalo-Cordeiro, C, Rodríguez-González, M, Rolla, G, Roller-Wirnsberger, RE, Romano, A, Bewick, M, Romano, M, Salimäki, J, Samolinski, B, Serpa, FS, Shamai, S, Sierra, M, Sova, M, Sorlini, M, Stellato, C, Stelmach, R, Bieber, T, Strandberg, T, Stroetmann, V, Stukas, R, Szylling, A, Tan, R, Tibaldi, V, Todo-Bom, A, Toppila-Salmi, S, Tomazic, P, Trama, U, Birov, S, and Triggiani, M
- Subjects
HEALTH-STATUS ,Science & Technology ,Allergy Diary ,Allergy ,CARAT ,IMPACT ,Immunology ,CARE PATHWAYS ,QUESTIONNAIRE ,asthma ,PARTNERSHIP ,WORK PRODUCTIVITY ,VALIDATION ,European Innovation Partnership on Active and Healthy Ageing ,rhinitis ,QUALITY-OF-LIFE ,1107 Immunology ,MASK-RHINITIS ,Life Sciences & Biomedicine ,EUROPEAN COUNTRIES - Abstract
The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives while ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study is to transfer innovation from an App developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will: (i) assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) study phenotypic characteristics and treatment over a period of one year of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults. This article is protected by copyright. All rights reserved.
- Published
- 2017
8. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
- Author
-
Bousquet, J, Onorato, GL, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, JC, Chavannes, NH, Cruz, AA, Keenoy, ED, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, PW, Illario, M, Ivancevich, JC, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A (Aziz), Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, JM, Bergmann, KC, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, GW, Cardona, V, Carriazo, AM, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, de Vries, G (Gerard), Fokkens, WJ, Fontaine, JF, Gemicioglu, B, Guldemond, Nick, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, ML, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melen, E, Menditto, E, Morais-Almeida, M, Mosges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pepin, JL, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, FER, Sova, M, Spranger, O, Stellato, C, Bom, AT, Tomazic, PV, Triggiani, M, Valero, A, Valovirta, E, Vandenplas, O, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, Senn, A, Bousquet, J, Onorato, GL, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, JC, Chavannes, NH, Cruz, AA, Keenoy, ED, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, PW, Illario, M, Ivancevich, JC, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A (Aziz), Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, JM, Bergmann, KC, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, GW, Cardona, V, Carriazo, AM, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, de Vries, G (Gerard), Fokkens, WJ, Fontaine, JF, Gemicioglu, B, Guldemond, Nick, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, ML, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melen, E, Menditto, E, Morais-Almeida, M, Mosges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pepin, JL, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, FER, Sova, M, Spranger, O, Stellato, C, Bom, AT, Tomazic, PV, Triggiani, M, Valero, A, Valovirta, E, Vandenplas, O, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, and Senn, A
- Published
- 2017
9. Construction d'un élément fini d'interface homogénéisé pour prendre en compte l'effet de la rugosité dans la modélisation des assemblages frettés
- Author
-
Boutoutaou, H, Fontaine, Jf, Bouaziz, Mohammed, Fontaine, Jean François, Département de Recherche en Ingéniérie des Véhicules pour l'Environnement ( DRIVE ), Université de Bourgogne ( UB ), Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de mécanique , ENP Alger, Ecole Nationale Polytechnique [Alger] ( ENP ), Département de Recherche en Ingéniérie des Véhicules pour l'Environnement (DRIVE), Université de Bourgogne (UB), Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, and Ecole Nationale Polytechnique [Alger] (ENP)
- Subjects
[ SPI.MECA.GEME ] Engineering Sciences [physics]/Mechanics [physics.med-ph]/Mechanical engineering [physics.class-ph] ,[SPI.MECA.GEME] Engineering Sciences [physics]/Mechanics [physics.med-ph]/Mechanical engineering [physics.class-ph] ,[SPI.MECA.GEME]Engineering Sciences [physics]/Mechanics [physics.med-ph]/Mechanical engineering [physics.class-ph] - Abstract
International audience; Le frettage est un procédé qui permet d'assembler deux pièces par serrage. Les méthodes de calcul traditionnelles considèrent ces pièces parfaites et ne prennent pas en compte leurs défauts géométriques (forme et états de surface). Ceci oblige généralement à utiliser des procédés onéreux pour obtenir ces surfaces. L'objectif des travaux présentés ici est de pouvoir intégrer le comportement de la micro géométrie des aspérités dans la modélisation des assemblages frettés. L'approche envisagée consiste à élaborer un élément d'interface présentant le comportement des aspérités. Le comportement de cet élément peut alors être défini par une relation entre son épaisseur (liée à la hauteur des aspérités) et la pression qui lui est appliquée. Un élément fini homogénéisé a été élaboré sur la base d'un comportement élastique isotrope transversalement. Ce comportement est identifié et validé sur la base de modélisations numériques. Une étude expérimentale sur des assemblages composés d'axes rectifiés en acier et de moyeux de formes extérieures circulaire et rectangulaire en duralumin, présentant divers niveaux de rugosité, serrage et défaut de forme, permet de vérifier la cohérence de l'approche. Les résultats obtenus sont globalement satisfaisants.
- Published
- 2013
10. PAL3 DEVELOPMENT, PILOT TESTING, SCORING AND VALIDATION OF A MANAGEMENT TOOL FOR PATIENTS UNDERGOING SPECIFIC IMMUNO-THERAPY
- Author
-
Arnould, B, primary, Benmedjahed, K, additional, Fadel, R, additional, Bos, C, additional, Fontaine, JF, additional, Haddad, T, additional, Mathelier Fusade, P, additional, Rufin, P, additional, Saint Martin, F, additional, Zekri, J, additional, and Viala, M, additional
- Published
- 2005
- Full Text
- View/download PDF
11. Allergie au latex chez 16 enfants
- Author
-
Sabouraud-Leclerc, D, primary, Fontaine, JF, additional, Lavaud, F, additional, Menu-Guillemin, S, additional, Capy, B, additional, Sulmont, V, additional, and Pennaforte, F, additional
- Published
- 1996
- Full Text
- View/download PDF
12. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024).
- Author
-
Bousquet J, Schünemann HJ, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, Bedbrook A, Czarlewski W, Hofmann-Apitius M, Litynska J, Vieira RJ, Anto JM, Fonseca JA, Brozek J, Bognanni A, Brussino L, Canonica GW, Cherrez-Ojeda I, Cruz AA, Vecillas LL, Dykewicz M, Gemicioglu B, Giovannini M, Haahtela T, Jacobs M, Jacomelli C, Klimek L, Kvedariene V, Larenas-Linnemann DE, Louis G, Lourenço O, Leemann L, Morais-Almeida M, Neves AL, Nadeau KC, Nowak A, Palamarchuk Y, Palkonen S, Papadopoulos NG, Parmelli E, Pereira AM, Pfaar O, Regateiro FS, Savouré M, Taborda-Barata L, Toppila-Salmi SK, Torres MJ, Valiulis A, Ventura MT, Williams S, Yepes-Nuñez JJ, Yorgancioglu A, Zhang L, Zuberbier J, Abdul Latiff AH, Abdullah B, Agache I, Al-Ahmad M, Al-Nesf MA, Al Shaikh NA, Amaral R, Ansotegui IJ, Asllani J, Balotro-Torres MC, Bergmann KC, Bernstein JA, Bindslev-Jensen C, Blaiss MS, Bonaglia C, Bonini M, Bossé I, Braido F, Caballero-Fonseca F, Camargos P, Carreiro-Martins P, Casale T, Castillo-Vizuete JA, Cecchi L, Teixeira MDC, Chang YS, Loureiro CC, Christoff G, Ciprandi G, Cirule I, Correia-de-Sousa J, Costa EM, Cvetkovski B, de Vries G, Del Giacco S, Devillier P, Dokic D, Douagui H, Durham SR, Enecilla ML, Fiocchi A, Fokkens WJ, Fontaine JF, Gawlik R, Gereda JE, Gil-Mata S, Giuliano AFM, Gotua M, Gradauskiene B, Guzman MA, Hossny E, Hrubiško M, Iinuma T, Irani C, Ispayeva Z, Ivancevich JC, Jartti T, Jeseňák M, Julge K, Jutel M, Kaidashev I, Bennoor KS, Khaltaev N, Kirenga B, Kraxner H, Kull I, Kulus M, Kuna P, Kupczyk M, Kurchenko A, La Grutta S, Lane S, Miculinic N, Lee SM, Le Thi Tuyet L, Lkhagvaa B, Louis R, Mahboub B, Makela M, Makris M, Maurer M, Melén E, Milenkovic B, Mohammad Y, Moniuszko M, Montefort S, Moreira A, Moreno P, Mullol J, Nadif R, Nakonechna A, Navarro-Locsin CG, Neffen HE, Nekam K, Niedoszytko M, Nunes E, Nyembue D, O'Hehir R, Ollert M, Ohta K, Okamoto Y, Okubo K, Olze H, Padukudru MA, Palomares O, Pali-Schöll I, Panzner P, Palosuo K, Park HS, Passalacqua G, Patella V, Pawankar R, Pétré B, Pitsios C, Plavec D, Popov TA, Puggioni F, Quirce S, Raciborski F, Ramonaité A, Recto M, Repka-Ramirez S, Roberts G, Robles-Velasco K, Roche N, Rodriguez-Gonzalez M, Romualdez JA, Rottem M, Rouadi PW, Salapatas M, Sastre J, Serpa FS, Sayah Z, Scichilone N, Senna G, Sisul JC, Solé D, Soto-Martinez ME, Sova M, Sozinova O, Stevanovic K, Ulrik CS, Szylling A, Tan FM, Tantilipikorn P, Todo-Bom A, Tomic-Spiric V, Tsaryk V, Tsiligianni I, Urrutia-Pereira M, Rostan MV, Sofiev M, Valovirta E, Van Eerd M, Van Ganse E, Vasankari T, Vichyanond P, Viegi G, Wallace D, Wang Y, Waserman S, Wong G, Worm M, Yusuf OM, Zaitoun F, and Zidarn M
- Subjects
- Humans, Critical Pathways, Practice Guidelines as Topic, Patient-Centered Care, Asthma therapy, Artificial Intelligence, Rhinitis, Allergic therapy, Telemedicine
- Abstract
The traditional healthcare model is focused on diseases (medicine and natural science) and does not acknowledge patients' resources and abilities to be experts in their own lives based on their lived experiences. Improving healthcare safety, quality, and coordination, as well as quality of life, is an important aim in the care of patients with chronic conditions. Person-centered care needs to ensure that people's values and preferences guide clinical decisions. This paper reviews current knowledge to develop (1) digital care pathways for rhinitis and asthma multimorbidity and (2) digitally enabled, person-centered care.
1 It combines all relevant research evidence, including the so-called real-world evidence, with the ultimate goal to develop digitally enabled, patient-centered care. The paper includes (1) Allergic Rhinitis and its Impact on Asthma (ARIA), a 2-decade journey, (2) Grading of Recommendations, Assessment, Development and Evaluation (GRADE), the evidence-based model of guidelines in airway diseases, (3) mHealth impact on airway diseases, (4) From guidelines to digital care pathways, (5) Embedding Planetary Health, (6) Novel classification of rhinitis and asthma, (7) Embedding real-life data with population-based studies, (8) The ARIA-EAACI (European Academy of Allergy and Clinical Immunology) strategy for the management of airway diseases using digital biomarkers, (9) Artificial intelligence, (10) The development of digitally enabled, ARIA person-centered care, and (11) The political agenda. The ultimate goal is to propose ARIA 2024 guidelines centered around the patient to make them more applicable and sustainable., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
13. Overlooked poor-quality patient samples in sequencing data impair reproducibility of published clinically relevant datasets.
- Author
-
Sprang M, Möllmann J, Andrade-Navarro MA, and Fontaine JF
- Subjects
- Humans, Reproducibility of Results, Sequence Analysis, RNA
- Abstract
Background: Reproducibility is a major concern in biomedical studies, and existing publication guidelines do not solve the problem. Batch effects and quality imbalances between groups of biological samples are major factors hampering reproducibility. Yet, the latter is rarely considered in the scientific literature., Results: Our analysis uses 40 clinically relevant RNA-seq datasets to quantify the impact of quality imbalance between groups of samples on the reproducibility of gene expression studies. High-quality imbalance is frequent (14 datasets; 35%), and hundreds of quality markers are present in more than 50% of the datasets. Enrichment analysis suggests common stress-driven effects among the low-quality samples and highlights a complementary role of transcription factors and miRNAs to regulate stress response. Preliminary ChIP-seq results show similar trends. Quality imbalance has an impact on the number of differential genes derived by comparing control to disease samples (the higher the imbalance, the higher the number of genes), on the proportion of quality markers in top differential genes (the higher the imbalance, the higher the proportion; up to 22%) and on the proportion of known disease genes in top differential genes (the higher the imbalance, the lower the proportion). We show that removing outliers based on their quality score improves the resulting downstream analysis., Conclusions: Thanks to a stringent selection of well-designed datasets, we demonstrate that quality imbalance between groups of samples can significantly reduce the relevance of differential genes, consequently reducing reproducibility between studies. Appropriate experimental design and analysis methods can substantially reduce the problem., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Molecular allergology: a clinical laboratory tool for precision diagnosis, stratification and follow-up of allergic patients.
- Author
-
Giusti D, Guemari A, Perotin JM, Fontaine JF, Tonye Libyh M, Gatouillat G, Tabary T, Pham BN, and Vitte J
- Subjects
- Humans, Allergens immunology, Follow-Up Studies, Laboratories, Clinical, Hypersensitivity diagnosis, Hypersensitivity immunology, Precision Medicine
- Abstract
Identification of the molecular culprits of allergic reactions leveraged molecular allergology applications in clinical laboratory medicine. Molecular allergology shifted the focus from complex, heterogeneous allergenic extracts, e.g. pollen, food, or insect venom, towards genetically and immunologically defined proteins available for in vitro diagnosis. Molecular allergology is a precision medicine approach for the diagnosis, stratification, therapeutic management, follow-up and prognostic evaluation of patients within a large range of allergic diseases. Exclusively available for in vitro diagnosis, molecular allergology is nonredundant with any of the current clinical tools for allergy investigation. As an example of a major application, discrimination of genuine sensitization from allergen cross-reactivity at the molecular level allows the proper targeting of the culprit allergen and thus dramatically improves patient management. This review aims at introducing clinical laboratory specialists to molecular allergology, from the biochemical and genetic bases, through immunological concepts, to daily use in the diagnosis and management of allergic diseases., (© 2024 Walter de Gruyter GmbH, Berlin/Boston.)
- Published
- 2024
- Full Text
- View/download PDF
15. A Systematic Review of Lipid-Focused Cardiovascular Disease Research: Trends and Opportunities.
- Author
-
Anyaegbunam UA, More P, Fontaine JF, Cate VT, Bauer K, Distler U, Araldi E, Bindila L, Wild P, and Andrade-Navarro MA
- Abstract
Lipids are important modifiers of protein function, particularly as parts of lipoproteins, which transport lipophilic substances and mediate cellular uptake of circulating lipids. As such, lipids are of particular interest as blood biological markers for cardiovascular disease (CVD) as well as for conditions linked to CVD such as atherosclerosis, diabetes mellitus, obesity and dietary states. Notably, lipid research is particularly well developed in the context of CVD because of the relevance and multiple causes and risk factors of CVD. The advent of methods for high-throughput screening of biological molecules has recently resulted in the generation of lipidomic profiles that allow monitoring of lipid compositions in biological samples in an untargeted manner. These and other earlier advances in biomedical research have shaped the knowledge we have about lipids in CVD. To evaluate the knowledge acquired on the multiple biological functions of lipids in CVD and the trends in their research, we collected a dataset of references from the PubMed database of biomedical literature focused on plasma lipids and CVD in human and mouse. Using annotations from these records, we were able to categorize significant associations between lipids and particular types of research approaches, distinguish non-biological lipids used as markers, identify differential research between human and mouse models, and detect the increasingly mechanistic nature of the results in this field. Using known associations between lipids and proteins that metabolize or transport them, we constructed a comprehensive lipid-protein network, which we used to highlight proteins strongly connected to lipids found in the CVD-lipid literature. Our approach points to a series of proteins for which lipid-focused research would bring insights into CVD, including Prostaglandin G/H synthase 2 (PTGS2, a.k.a. COX2) and Acylglycerol kinase (AGK). In this review, we summarize our findings, putting them in a historical perspective of the evolution of lipid research in CVD.
- Published
- 2023
- Full Text
- View/download PDF
16. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air ® approach.
- Author
-
Bousquet J, Anto JM, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahtela T, Klimek L, Pfaar O, Kuna P, Kupczyk M, Regateiro FS, Samolinski B, Valiulis A, Yorgancioglu A, Arnavielhe S, Basagaña X, Bergmann KC, Bosnic-Anticevich S, Brussino L, Canonica GW, Cardona V, Cecchi L, Chaves-Loureiro C, Costa E, Cruz AA, Gemicioglu B, Fokkens WJ, Ivancevich JC, Kraxner H, Kvedariene V, Larenas-Linnemann DE, Laune D, Louis R, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedoszytko M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Rouadi PW, Sastre J, Scichilone N, Sheikh A, Sofiev M, Taborda-Barata L, Toppila-Salmi S, Tsiligianni I, Valovirta E, Ventura MT, Vieira RJ, Zidarn M, Amaral R, Ansotegui IJ, Bédard A, Benveniste S, Bewick M, Bindslev-Jensen C, Blain H, Bonini M, Bourret R, Braido F, Carreiro-Martins P, Charpin D, Cherrez-Ojeda I, Chivato T, Chu DK, Cingi C, Del Giacco S, de Blay F, Devillier P, De Vries G, Doulaptsi M, Doyen V, Dray G, Fontaine JF, Gomez RM, Hagemann J, Heffler E, Hofmann M, Jassem E, Jutel M, Keil T, Kritikos V, Kull I, Kulus M, Lourenço O, Mathieu-Dupas E, Menditto E, Mösges R, Murray R, Nadif R, Neffen H, Nicola S, O'Hehir R, Olze H, Palamarchuk Y, Pépin JL, Pétré B, Picard R, Pitsios C, Puggioni F, Quirce S, Raciborski F, Reitsma S, Roche N, Rodriguez-Gonzalez M, Romantowski J, Sá-Sousa A, Serpa FS, Savouré M, Shamji MH, Sova M, Sperl A, Stellato C, Todo-Bom A, Tomazic PV, Vandenplas O, Van Eerd M, Vasankari T, Viart F, Waserman S, Fonseca JA, and Zuberbier T
- Abstract
MASK-air
® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma., (© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)- Published
- 2023
- Full Text
- View/download PDF
17. Batch effect detection and correction in RNA-seq data using machine-learning-based automated assessment of quality.
- Author
-
Sprang M, Andrade-Navarro MA, and Fontaine JF
- Subjects
- Cluster Analysis, Machine Learning, RNA-Seq, Algorithms, Software
- Abstract
Background: The constant evolving and development of next-generation sequencing techniques lead to high throughput data composed of datasets that include a large number of biological samples. Although a large number of samples are usually experimentally processed by batches, scientific publications are often elusive about this information, which can greatly impact the quality of the samples and confound further statistical analyzes. Because dedicated bioinformatics methods developed to detect unwanted sources of variance in the data can wrongly detect real biological signals, such methods could benefit from using a quality-aware approach., Results: We recently developed statistical guidelines and a machine learning tool to automatically evaluate the quality of a next-generation-sequencing sample. We leveraged this quality assessment to detect and correct batch effects in 12 publicly available RNA-seq datasets with available batch information. We were able to distinguish batches by our quality score and used it to correct for some batch effects in sample clustering. Overall, the correction was evaluated as comparable to or better than the reference method that uses a priori knowledge of the batches (in 10 and 1 datasets of 12, respectively; total = 92%). When coupled to outlier removal, the correction was more often evaluated as better than the reference (comparable or better in 5 and 6 datasets of 12, respectively; total = 92%)., Conclusions: In this work, we show the capabilities of our software to detect batches in public RNA-seq datasets from differences in the predicted quality of their samples. We also use these insights to correct the batch effect and observe the relation of sample quality and batch effect. These observations reinforce our expectation that while batch effects do correlate with differences in quality, batch effects also arise from other artifacts and are more suitably corrected statistically in well-designed experiments., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
18. Single-cell specific and interpretable machine learning models for sparse scChIP-seq data imputation.
- Author
-
Albrecht S, Andreani T, Andrade-Navarro MA, and Fontaine JF
- Subjects
- Animals, Cluster Analysis, DNA, Mice, Sequence Analysis, DNA methods, Genomics, Machine Learning
- Abstract
Motivation: Single-cell Chromatin ImmunoPrecipitation DNA-Sequencing (scChIP-seq) analysis is challenging due to data sparsity. High degree of sparsity in biological high-throughput single-cell data is generally handled with imputation methods that complete the data, but specific methods for scChIP-seq are lacking. We present SIMPA, a scChIP-seq data imputation method leveraging predictive information within bulk data from the ENCODE project to impute missing protein-DNA interacting regions of target histone marks or transcription factors., Results: Imputations using machine learning models trained for each single cell, each ChIP protein target, and each genomic region accurately preserve cell type clustering and improve pathway-related gene identification on real human data. Results on bulk data simulating single cells show that the imputations are single-cell specific as the imputed profiles are closer to the simulated cell than to other cells related to the same ChIP protein target and the same cell type. Simulations also show that 100 input genomic regions are already enough to train single-cell specific models for the imputation of thousands of undetected regions. Furthermore, SIMPA enables the interpretation of machine learning models by revealing interaction sites of a given single cell that are most important for the imputation model trained for a specific genomic region. The corresponding feature importance values derived from promoter-interaction profiles of H3K4me3, an activating histone mark, highly correlate with co-expression of genes that are present within the cell-type specific pathways in 2 real human and mouse datasets. The SIMPA's interpretable imputation method allows users to gain a deep understanding of individual cells and, consequently, of sparse scChIP-seq datasets., Availability and Implementation: Our interpretable imputation algorithm was implemented in Python and is available at https://github.com/salbrec/SIMPA., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
19. Annotation and Analysis of 3902 Odorant Receptor Protein Sequences from 21 Insect Species Provide Insights into the Evolution of Odorant Receptor Gene Families in Solitary and Social Insects.
- Author
-
Mier P, Fontaine JF, Stoldt M, Libbrecht R, Martelli C, Foitzik S, and Andrade-Navarro MA
- Subjects
- Animals, Drosophila melanogaster metabolism, Insect Proteins metabolism, Insecta genetics, Insecta metabolism, Ligands, Receptors, Odorant genetics, Receptors, Odorant metabolism
- Abstract
The gene family of insect olfactory receptors (ORs) has expanded greatly over the course of evolution. ORs enable insects to detect volatile chemicals and therefore play an important role in social interactions, enemy and prey recognition, and foraging. The sequences of several thousand ORs are known, but their specific function or their ligands have only been identified for very few of them. To advance the functional characterization of ORs, we have assembled, curated, and aligned the sequences of 3902 ORs from 21 insect species, which we provide as an annotated online resource. Using functionally characterized proteins from the fly Drosophila melanogaster , the mosquito Anopheles gambiae and the ant Harpegnathos saltator , we identified amino acid positions that best predict response to ligands. We examined the conservation of these predicted relevant residues in all OR subfamilies; the results showed that the subfamilies that expanded strongly in social insects had a high degree of conservation in their binding sites. This suggests that the ORs of social insect families are typically finely tuned and exhibit sensitivity to very similar odorants. Our novel approach provides a powerful tool to exploit functional information from a limited number of genes to study the functional evolution of large gene families.
- Published
- 2022
- Full Text
- View/download PDF
20. LipiDisease: associate lipids to diseases using literature mining.
- Author
-
More P, Bindila L, Wild P, Andrade-Navarro M, and Fontaine JF
- Subjects
- PubMed, Databases, Factual, Data Mining, Software, Lipids analysis
- Abstract
Summary: Lipids exhibit an essential role in cellular assembly and signaling. Dysregulation of these functions has been linked with many complications including obesity, diabetes, metabolic disorders, cancer and more. Investigating lipid profiles in such conditions can provide insights into cellular functions and possible interventions. Hence the field of lipidomics is expanding in recent years. Even though the role of individual lipids in diseases has been investigated, there is no resource to perform disease enrichment analysis considering the cumulative association of a lipid set. To address this, we have implemented the LipiDisease web server. The tool analyzes millions of records from the PubMed biomedical literature database discussing lipids and diseases, predicts their association and ranks them according to false discovery rates generated by random simulations. The tool takes into account 4270 diseases and 4798 lipids. Since the tool extracts the information from PubMed records, the number of diseases and lipids will be expanded over time as the biomedical literature grows., Availability and Implementation: The LipiDisease webserver can be freely accessed at http://cbdm-01.zdv.uni-mainz.de:3838/piyusmor/LipiDisease/., Supplementary Information: Supplementary data are available at Bioinformatics online., (© The Author(s) 2021. Published by Oxford University Press.)
- Published
- 2021
- Full Text
- View/download PDF
21. Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT.
- Author
-
Devall A, Chu J, Beeson L, Hardy P, Cheed V, Sun Y, Roberts T, Ogwulu CO, Williams E, Jones L, Papadopoulos JF, Bender-Atik R, Brewin J, Hinshaw K, Choudhary M, Ahmed A, Naftalin J, Nunes N, Oliver A, Izzat F, Bhatia K, Hassan I, Jeve Y, Hamilton J, Deb S, Bottomley C, Ross J, Watkins L, Underwood M, Cheong Y, Kumar C, Gupta P, Small R, Pringle S, Hodge F, Shahid A, Gallos I, Horne A, Quenby S, and Coomarasamy A
- Subjects
- Cost-Benefit Analysis, Female, Humans, Mifepristone therapeutic use, Pregnancy, Technology Assessment, Biomedical, Abortion, Spontaneous drug therapy, Misoprostol therapeutic use
- Abstract
Trial Design: A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne
® , Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarriage., Methods: Women diagnosed with missed miscarriage in the first 14 weeks of pregnancy were randomly assigned (1 : 1 ratio) to receive 200 mg of oral mifepristone or matched placebo, followed by 800 μg of misoprostol 2 days later. A web-based randomisation system allocated the women to the two groups, with minimisation for age, body mass index, parity, gestational age, amount of bleeding and randomising centre. The primary outcome was failure to pass the gestational sac within 7 days after randomisation. The prespecified key secondary outcome was requirement for surgery to resolve the miscarriage. A within-trial cost-effectiveness study and a nested qualitative study were also conducted. Women who completed the trial protocol were purposively approached to take part in an interview to explore their satisfaction with and the acceptability of medical management of missed miscarriage., Results: A total of 711 women, from 28 hospitals in the UK, were randomised to receive either mifepristone plus misoprostol (357 women) or placebo plus misoprostol (354 women). The follow-up rate for the primary outcome was 98% (696 out of 711 women). The risk of failure to pass the gestational sac within 7 days was 17% (59 out of 348 women) in the mifepristone plus misoprostol group, compared with 24% (82 out of 348 women) in the placebo plus misoprostol group (risk ratio 0.73, 95% confidence interval 0.54 to 0.98; p = 0.04). Surgical intervention to resolve the miscarriage was needed in 17% (62 out of 355 women) in the mifepristone plus misoprostol group, compared with 25% (87 out of 353 women) in the placebo plus misoprostol group (risk ratio 0.70, 95% confidence interval 0.52 to 0.94; p = 0.02). There was no evidence of a difference in the incidence of adverse events between the two groups. A total of 42 women, 19 in the mifepristone plus misoprostol group and 23 in the placebo plus misoprostol group, took part in an interview. Women appeared to have a preference for active management of their miscarriage. Overall, when women experienced care that supported their psychological well-being throughout the care pathway, and information was delivered in a skilled and sensitive manner such that women felt informed and in control, they were more likely to express satisfaction with medical management. The use of mifepristone and misoprostol showed an absolute effect difference of 6.6% (95% confidence interval 0.7% to 12.5%). The average cost per woman was lower in the mifepristone plus misoprostol group, with a cost saving of £182 (95% confidence interval £26 to £338). Therefore, the use of mifepristone and misoprostol for the medical management of a missed miscarriage dominated the use of misoprostol alone., Limitations: The results from this trial are not generalisable to women diagnosed with incomplete miscarriage and the study does not allow for a comparison with expectant or surgical management of miscarriage., Future Work: Future work should use existing data to assess and rank the relative clinical effectiveness and safety profiles for all methods of management of miscarriage., Conclusions: Our trial showed that pre-treatment with mifepristone followed by misoprostol resulted in a higher rate of resolution of missed miscarriage than misoprostol treatment alone. Women were largely satisfied with medical management of missed miscarriage and would choose it again. The mifepristone and misoprostol intervention was shown to be cost-effective in comparison to misoprostol alone., Trial Registration: Current Controlled Trials ISRCTN17405024., Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 68. See the NIHR Journals Library website for further project information.- Published
- 2021
- Full Text
- View/download PDF
22. Posttranslational modifications by ADAM10 shape myeloid antigen-presenting cell homeostasis in the splenic marginal zone.
- Author
-
Diener N, Fontaine JF, Klein M, Hieronymus T, Wanke F, Kurschus FC, Ludwig A, Ware C, Saftig P, Bopp T, Clausen BE, and Backer RA
- Subjects
- ADAM10 Protein physiology, Amyloid Precursor Protein Secretases physiology, Animals, Antigen-Presenting Cells metabolism, CD11c Antigen metabolism, Cell Differentiation, Cell Proliferation, Female, Homeostasis, Lymphoid Tissue metabolism, Macrophages metabolism, Male, Membrane Proteins physiology, Mice, Mice, Inbred C57BL, Myeloid Cells metabolism, Phosphatidylinositol 3-Kinases metabolism, Protein Processing, Post-Translational genetics, Protein Processing, Post-Translational physiology, Signal Transduction, Spleen cytology, Spleen metabolism, ADAM10 Protein metabolism, Amyloid Precursor Protein Secretases metabolism, Dendritic Cells metabolism, Membrane Proteins metabolism
- Abstract
The spleen contains phenotypically and functionally distinct conventional dendritic cell (cDC) subpopulations, termed cDC1 and cDC2, which each can be divided into several smaller and less well-characterized subsets. Despite advances in understanding the complexity of cDC ontogeny by transcriptional programming, the significance of posttranslational modifications in controlling tissue-specific cDC subset immunobiology remains elusive. Here, we identified the cell-surface-expressed A-disintegrin-and-metalloproteinase 10 (ADAM10) as an essential regulator of cDC1 and cDC2 homeostasis in the splenic marginal zone (MZ). Mice with a CD11c-specific deletion of ADAM10 (ADAM10
ΔCD11c ) exhibited a complete loss of splenic ESAMhi cDC2A because ADAM10 regulated the commitment, differentiation, and survival of these cells. The major pathways controlled by ADAM10 in ESAMhi cDC2A are Notch, signaling pathways involved in cell proliferation and survival (e.g., mTOR, PI3K/AKT, and EIF2 signaling), and EBI2-mediated localization within the MZ. In addition, we discovered that ADAM10 is a molecular switch regulating cDC2 subset heterogeneity in the spleen, as the disappearance of ESAMhi cDC2A in ADAM10ΔCD11c mice was compensated for by the emergence of a Clec12a+ cDC2B subset closely resembling cDC2 generally found in peripheral lymph nodes. Moreover, in ADAM10ΔCD11c mice, terminal differentiation of cDC1 was abrogated, resulting in severely reduced splenic Langerin+ cDC1 numbers. Next to the disturbed splenic cDC compartment, ADAM10 deficiency on CD11c+ cells led to an increase in marginal metallophilic macrophage (MMM) numbers. In conclusion, our data identify ADAM10 as a molecular hub on both cDC and MMM regulating their transcriptional programming, turnover, homeostasis, and ability to shape the anatomical niche of the MZ., Competing Interests: The authors declare no competing interest.- Published
- 2021
- Full Text
- View/download PDF
23. Statistical guidelines for quality control of next-generation sequencing techniques.
- Author
-
Sprang M, Krüger M, Andrade-Navarro MA, and Fontaine JF
- Subjects
- Computational Biology methods, Genome, Human, Humans, Quality Control, Sequence Analysis, DNA statistics & numerical data, Software, High-Throughput Nucleotide Sequencing methods, High-Throughput Nucleotide Sequencing standards, Sequence Analysis, DNA methods
- Abstract
More and more next-generation sequencing (NGS) data are made available every day. However, the quality of this data is not always guaranteed. Available quality control tools require profound knowledge to correctly interpret the multiplicity of quality features. Moreover, it is usually difficult to know if quality features are relevant in all experimental conditions. Therefore, the NGS community would highly benefit from condition-specific data-driven guidelines derived from many publicly available experiments, which reflect routinely generated NGS data. In this work, we have characterized well-known quality guidelines and related features in big datasets and concluded that they are too limited for assessing the quality of a given NGS file accurately. Therefore, we present new data-driven guidelines derived from the statistical analysis of many public datasets using quality features calculated by common bioinformatics tools. Thanks to this approach, we confirm the high relevance of genome mapping statistics to assess the quality of the data, and we demonstrate the limited scope of some quality features that are not relevant in all conditions. Our guidelines are available at https://cbdm.uni-mainz.de/ngs-guidelines., (© 2021 Sprang et al.)
- Published
- 2021
- Full Text
- View/download PDF
24. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.
- Author
-
Bousquet J, Pfaar O, Agache I, Bedbrook A, Akdis CA, Canonica GW, Chivato T, Al-Ahmad M, Abdul Latiff AH, Ansotegui IJ, Bachert C, Baharuddin A, Bergmann KC, Bindslev-Jensen C, Bjermer L, Bonini M, Bosnic-Anticevich S, Bosse I, Brough HA, Brussino L, Calderon MA, Caraballo L, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Cepeda Sarabia AM, Chkhartishvili E, Chu DK, Cirule I, Cruz AA, Czarlewski W, Del Giacco S, Demoly P, Devillier P, Dokic D, Durham SL, Ebisawa M, El-Gamal Y, Emuzyte R, Gamkrelidze A, Fauquert JL, Fiocchi A, Fokkens WJ, Fonseca JA, Fontaine JF, Gawlik R, Gelincik A, Gemicioglu B, Gereda JE, Gerth van Wijk R, Gomez RM, Gotua M, Grisle I, Guzmán MA, Haahtela T, Halken S, Heffler E, Hoffmann-Sommergruber K, Hossny E, Hrubiško M, Irani C, Ivancevich JC, Ispayeva Z, Julge K, Kaidashev I, Kalayci O, Khaitov M, Klimek L, Knol E, Kowalski ML, Kraxner H, Kull I, Kuna P, Kvedariene V, Kritikos V, Lauerma A, Lau S, Laune D, Levin M, Larenas-Linnemann DE, Lodrup Carlsen KC, Lombardi C, Lourenço OM, Mahboub B, Malling HJ, Manning P, Marshall GD, Melén E, Meltzer EO, Miculinic N, Milenkovic B, Moin M, Montefort S, Morais-Almeida M, Mortz CG, Mösges R, Mullol J, Namazova Baranova L, Neffen H, Nekam K, Niedoszytko M, Odemyr M, O'Hehir RE, Ollert M, O'Mahony L, Ohta K, Okamoto Y, Okubo K, Pajno GB, Palomares O, Palkonen S, Panzner P, G Papadopoulos N, Park HS, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Plavec D, Popov TA, Recto M, Regateiro FS, Riggioni C, Roberts G, Rodriguez-Gonzales M, Rosario N, Rottem M, Rouadi PW, Ryan D, Samolinski B, Sanchez-Borges M, Serpa FS, Sastre J, Scadding GK, Shamji MH, Schmid-Grendelmeier P, Schünemann HJ, Sheikh A, Scichilone N, Sisul JC, Sofiev M, Solé D, Sooronbaev T, Soto-Martinez M, Soto-Quiros M, Sova M, Schwarze J, Skypala I, Suppli-Ulrik C, Taborda-Barata L, Todo-Bom A, Torres MJ, Valentin-Rostan M, Tomazic PV, Valero A, Toppila-Salmi S, Tsiligianni I, Untersmayr E, Urrutia-Pereira M, Valiulis A, Valovirta E, Vandenplas O, Ventura MT, Vichyanond P, Wagenmann M, Wallace D, Walusiak-Skorupa J, Wang Y, Waserman S, Wong GW, Yorgancioglu A, Yusuf OM, Zernotti M, Zhang L, Zidarn M, Zuberbier T, and Jutel M
- Abstract
Competing Interests: IAgache is an Associate Editor Allergy and CTA. CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, scibase, advisory role in Sanofi/Regeneron, grants from Glakso Smith‐Kline, advisory role in scibase. IA reports personal fees from Hikma, Roxall, Astra Zeneca, Menarini, UCB, Faes Farma, Sanofi, Mundipharma, Bial, Amgen, Stallergenes. SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. VC reports personal fees from ALK, Allergy Therapeutics, LETI, Thermofisher, Merck, Astrazeneca, GSK. TC reports grants and personal fees from Stallergenes. PD reports personal fees from ALK‐Abello, Stallergenes‐Greer, Astra Zeneca, GlaxoSmithKline, Mylan, Sanofi. SD reports personal fees and non‐financial support from ALK Abello, personal fees from Adiga, Biomay, Allergopharma, Anergis, Allergy Therapeutics. TH reports personal fees from GSK, Mundipharma, Orion Pharma. SH reports other from ALK‐Abelló, other from ALK‐Abelló. EH reports personal fees from Sanofi, Novartis, GSK, AstraZeneca, Circassia, Nestlè Purina. JCI reports personal fees from Faes Farma, Laboratorios Casasco Argentina, Abbott de Ecuador, EuroFarma Argentina. MJ reports personal fees from ALK‐Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, HAL, during the conduct of the study; personal fees from Astra‐Zeneka, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, Chiesi,. LK reports grants and personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi, grants from Stallergenes, Quintiles, ASIT biotech, grants from ALK Abelló, Lofarma, AstraZeneca, GSK, Inmunotk, personal fees from Allergy Therapeut., HAL Allergie, Cassella med; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. PK reports personal fees from Adamed, Berlin Chemie Menarini, Boehringer Ingelheim, AstraZeneca, Lekam, Novartis, Polpharma, GSK, Polpharma, Sanofi, teva. VK reports other from GSK, non‐financial support from Mylan, AstraZeneca, Dimuna, Norameda. SL reports personal fees from DBV, Sanofi Aventis, Allergopharma, ALK, Nutricia, Bencard. EM reports personal fees from Sanofi, Novartis, AstraZeneca and Chiesi. JM reports personal fees and other from SANOFI‐GENZYME & REGENERON, NOVARTIS, ALLAKOS, MITSUBISHI‐TANABE, MENARINI, UCB, ASTRAZENECA, GSK, MSD, grants and personal fees from MYLAN‐MEDA Pharma, URIACH Group. MO reports personal fees from Hycor Diagnostics, Thermo Fisher Phadia. YO reports personal fees from Torii Pharmaceutical Co., Ltd., Shionogi Pharmaceutical Co.,Ltd. OP received research grants from Inmunotek S.L., Novartis and MINECO and has received fees for giving scientific lectures or participation in Advisory Boards from: Allergy Therapeutics, Amgen, AstraZeneca, Diater, GlaxoSmithKline, S.A, Inmunotek S.L, Novartis, Sanofi‐Genzyme and Stallergenes. NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, Inmunotek S.L., personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS. DPreports grants and personal fees from GlaxoSmithKline, personal fees from Menarini, Pliva, Belupo, AbbVie, Novartis, MSD, Chiesi, Revenio, personal fees and non‐financial support from Boehringer Ingelheim, non‐financial support from Philips. MR is on the Advisory board‐ A. Menarini ‐ Speaker ‐ Astra Zeneca, Novartis, Sanofi, Mylan. FSRreports speaker and advisory fees from AstraZeneca, Novartis, Sanofi, GSK, Teva and Lusomedicamenta. GR reports payment to his Institution from Allergo Pharma. BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. JS reports grants and personal fees from Sanofi, personal fees from GSK, Novartis, Astra Zeneca, Mundipharma, Faes Farma. GS reports personal fees from ALK, and leds on the BSACI Rhinitis Guidelines and lead for EUFOREA on Allergic Rhinitis. PSG reports personal fees from Allergopharma, ALK, grants from Bencard, grants and personal fees from Stallergenes. JS reports personal fees from Mylan, F2F events. ATB reports grants and personal fees from Teva, AstraZeneca, GSK Sanofi, Mundipharma, personal fees from Bial, Novartis. MJTreports grants from European Commission, SEAIC, ISCIII, personal fees from Diater laboratory, Leti laboratory, Aimmune Therapeutics. MW reports personal fees from ALK‐Abello, Allergopharma, AstraZeneca, Bencard, Genzyme, GlaxoSmithKline, HAL Allergy, LETI, Meda Pharma, Novartis, Sanofi, Stallergenes, Teva. DW reports other from Optinose, ALK, Sanofi; past Co‐Chair of the Joint Task Force on Practice Parameters of the AAAAI and ACAAI. Second author of a recently published practice parameter on Rhinitis. MW reports other from Aralez (Medexus), Pediapharm, Pfizer, Astra Zeneca, GSK, Alk. MZ reports personal fees from Takeda. TZ reports and Organizational affiliations: Commitee member: WHO‐Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF). Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). FIGURE 1Countries with Pocket Guide membersFIGURE 2Proposed Flow of Precision Medicine approach in allergic diseases. *examples of exceptions: Thunderstorm‐induced asthma, patient with moderate rhinitis and severe asthma during pollen seasonFIGURE 3Treatment algorithm using visual analogue scale (VAS) for adolescents and adults AIT, allergen immunotherapy; VAS, visual analogue scale.FIGURE 4Algorithm for AIT in asthma
- Published
- 2021
- Full Text
- View/download PDF
25. [Let's walk the web while COVID is here].
- Author
-
Fontaine JF and Didier A
- Published
- 2021
- Full Text
- View/download PDF
26. DiseaseLinc: Disease Enrichment Analysis of Sets of Differentially Expressed LincRNAs.
- Author
-
More P, Talyan S, Fontaine JF, Muro EM, and Andrade-Navarro MA
- Subjects
- Breast Neoplasms genetics, Female, Gene Expression Regulation, Neoplastic, Humans, Internet, Kaplan-Meier Estimate, Prognosis, RNA, Long Noncoding metabolism, User-Computer Interface, Disease genetics, Gene Expression Profiling, RNA, Long Noncoding genetics
- Abstract
Long intergenic non-coding RNAs (LincRNAs) are long RNAs that do not encode proteins. Functional evidence is lacking for most of them. Their biogenesis is not well-known, but it is thought that many lincRNAs originate from genomic duplication of coding material, resulting in pseudogenes, gene copies that lose their original function and can accumulate mutations. While most pseudogenes eventually stop producing a transcript and become erased by mutations, many of these pseudogene-based lincRNAs keep similarity to the parental gene from which they originated, possibly for functional reasons. For example, they can act as decoys for miRNAs targeting the parental gene. Enrichment analysis of function is a powerful tool to discover the functional effects of a treatment producing differential expression of transcripts. However, in the case of lincRNAs, since their function is not easy to define experimentally, such a tool is lacking. To address this problem, we have developed an enrichment analysis tool that focuses on lincRNAs exploiting their functional association, using as a proxy function that of the parental genes and has a focus on human diseases.
- Published
- 2021
- Full Text
- View/download PDF
27. seqQscorer: automated quality control of next-generation sequencing data using machine learning.
- Author
-
Albrecht S, Sprang M, Andrade-Navarro MA, and Fontaine JF
- Subjects
- Algorithms, Computational Biology standards, Databases, Genetic, Genomics methods, Genomics standards, ROC Curve, Reproducibility of Results, Workflow, Computational Biology methods, High-Throughput Nucleotide Sequencing methods, Machine Learning, Quality Control, Software
- Abstract
Controlling quality of next-generation sequencing (NGS) data files is a necessary but complex task. To address this problem, we statistically characterize common NGS quality features and develop a novel quality control procedure involving tree-based and deep learning classification algorithms. Predictive models, validated on internal and external functional genomics datasets, are to some extent generalizable to data from unseen species. The derived statistical guidelines and predictive models represent a valuable resource for users of NGS data to better understand quality issues and perform automatic quality control. Our guidelines and software are available at https://github.com/salbrec/seqQscorer .
- Published
- 2021
- Full Text
- View/download PDF
28. Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions.
- Author
-
Barakat L, Torres MJ, Phillips EJ, Caminati M, Chang YS, Caimmi D, Sanchez-Borges M, Rosenwasser L, Didier A, de Blay F, Fontaine JF, Bosse I, Lefevre S, Bassani C, De Filippo M, Asontegui I, Morais-Almeida M, Ebisawa M, Martin B, Thong BY, Demoly P, and Tanno LK
- Subjects
- Humans, Skin Tests, Drug Hypersensitivity diagnosis, Drug Hypersensitivity therapy, Hypersensitivity therapy
- Published
- 2021
- Full Text
- View/download PDF
29. Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic.
- Author
-
Tanno LK, Demoly P, Martin B, Berstein J, Morais-Almeida M, Levin M, Fiocchi A, Sánchez-Borges M, Caraballo LR, Wong G, Ortega-Martell JA, Rouadi P, Yáñez A, Wang LL, Peden DB, Chikhladze M, González-Díaz SN, Fontaine JF, Sublett J, Chang YS, Passalacqua G, Ansotegui IJ, Ebisawa M, Senna G, and Caminati M
- Abstract
Background: The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic., Methods: We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context., Results: Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as "I have no data" or "I don't know" to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations., Conclusion: The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems., Competing Interests: The authors declare that they do not have conflict of interests related to the contents of this article., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
30. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice.
- Author
-
Bousquet J, Anto JM, Bachert C, Haahtela T, Zuberbier T, Czarlewski W, Bedbrook A, Bosnic-Anticevich S, Walter Canonica G, Cardona V, Costa E, Cruz AA, Erhola M, Fokkens WJ, Fonseca JA, Illario M, Ivancevich JC, Jutel M, Klimek L, Kuna P, Kvedariene V, Le L, Larenas-Linnemann DE, Laune D, Lourenço OM, Melén E, Mullol J, Niedoszytko M, Odemyr M, Okamoto Y, Papadopoulos NG, Patella V, Pfaar O, Pham-Thi N, Rolland C, Samolinski B, Sheikh A, Sofiev M, Suppli Ulrik C, Todo-Bom A, Tomazic PV, Toppila-Salmi S, Tsiligianni I, Valiulis A, Valovirta E, Ventura MT, Walker S, Williams S, Yorgancioglu A, Agache I, Akdis CA, Almeida R, Ansotegui IJ, Annesi-Maesano I, Arnavielhe S, Basagaña X, D Bateman E, Bédard A, Bedolla-Barajas M, Becker S, Bennoor KS, Benveniste S, Bergmann KC, Bewick M, Bialek S, E Billo N, Bindslev-Jensen C, Bjermer L, Blain H, Bonini M, Bonniaud P, Bosse I, Bouchard J, Boulet LP, Bourret R, Boussery K, Braido F, Briedis V, Briggs A, Brightling CE, Brozek J, Brusselle G, Brussino L, Buhl R, Buonaiuto R, Calderon MA, Camargos P, Camuzat T, Caraballo L, Carriazo AM, Carr W, Cartier C, Casale T, Cecchi L, Cepeda Sarabia AM, H Chavannes N, Chkhartishvili E, Chu DK, Cingi C, Correia de Sousa J, Costa DJ, Courbis AL, Custovic A, Cvetkosvki B, D'Amato G, da Silva J, Dantas C, Dokic D, Dauvilliers Y, De Feo G, De Vries G, Devillier P, Di Capua S, Dray G, Dubakiene R, Durham SR, Dykewicz M, Ebisawa M, Gaga M, El-Gamal Y, Heffler E, Emuzyte R, Farrell J, Fauquert JL, Fiocchi A, Fink-Wagner A, Fontaine JF, Fuentes Perez JM, Gemicioğlu B, Gamkrelidze A, Garcia-Aymerich J, Gevaert P, Gomez RM, González Diaz S, Gotua M, Guldemond NA, Guzmán MA, Hajjam J, Huerta Villalobos YR, Humbert M, Iaccarino G, Ierodiakonou D, Iinuma T, Jassem E, Joos G, Jung KS, Kaidashev I, Kalayci O, Kardas P, Keil T, Khaitov M, Khaltaev N, Kleine-Tebbe J, Kouznetsov R, Kowalski ML, Kritikos V, Kull I, La Grutta S, Leonardini L, Ljungberg H, Lieberman P, Lipworth B, Lodrup Carlsen KC, Lopes-Pereira C, Loureiro CC, Louis R, Mair A, Mahboub B, Makris M, Malva J, Manning P, Marshall GD, Masjedi MR, Maspero JF, Carreiro-Martins P, Makela M, Mathieu-Dupas E, Maurer M, De Manuel Keenoy E, Melo-Gomes E, Meltzer EO, Menditto E, Mercier J, Micheli Y, Miculinic N, Mihaltan F, Milenkovic B, Mitsias DI, Moda G, Mogica-Martinez MD, Mohammad Y, Montefort S, Monti R, Morais-Almeida M, Mösges R, Münter L, Muraro A, Murray R, Naclerio R, Napoli L, Namazova-Baranova L, Neffen H, Nekam K, Neou A, Nordlund B, Novellino E, Nyembue D, O'Hehir R, Ohta K, Okubo K, Onorato GL, Orlando V, Ouedraogo S, Palamarchuk J, Pali-Schöll I, Panzner P, Park HS, Passalacqua G, Pépin JL, Paulino E, Pawankar R, Phillips J, Picard R, Pinnock H, Plavec D, Popov TA, Portejoie F, Price D, Prokopakis EP, Psarros F, Pugin B, Puggioni F, Quinones-Delgado P, Raciborski F, Rajabian-Söderlund R, Regateiro FS, Reitsma S, Rivero-Yeverino D, Roberts G, Roche N, Rodriguez-Zagal E, Rolland C, Roller-Wirnsberger RE, Rosario N, Romano A, Rottem M, Ryan D, Salimäki J, Sanchez-Borges MM, Sastre J, Scadding GK, Scheire S, Schmid-Grendelmeier P, Schünemann HJ, Sarquis Serpa F, Shamji M, Sisul JC, Sofiev M, Solé D, Somekh D, Sooronbaev T, Sova M, Spertini F, Spranger O, Stellato C, Stelmach R, Thibaudon M, To T, Toumi M, Usmani O, Valero AA, Valenta R, Valentin-Rostan M, Pereira MU, van der Kleij R, Van Eerd M, Vandenplas O, Vasankari T, Vaz Carneiro A, Vezzani G, Viart F, Viegi G, Wallace D, Wagenmann M, Wang Y, Waserman S, Wickman M, Williams DM, Wong G, Wroczynski P, Yiallouros PK, Yusuf OM, Zar HJ, Zeng S, Zernotti ME, Zhang L, Shan Zhong N, and Zidarn M
- Subjects
- Humans, Asthma, Respiration Disorders, Rhinitis, Allergic
- Abstract
Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed., (© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
31. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study.
- Author
-
Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S, Bedbrook A, Onorato GL, Czarlewski W, Murray R, Almeida R, Fonseca JA, Correia da Sousa J, Costa E, Morais-Almeida M, Todo-Bom A, Cecchi L, De Feo G, Illario M, Menditto E, Monti R, Stellato C, Ventura MT, Annesi-Maesano I, Bosse I, Fontaine JF, Pham-Thi N, Thibaudon M, Schmid-Grendelmeier P, Spertini F, Chavannes NH, Fokkens WJ, Reitsma S, Dubakiene R, Emuzyte R, Kvedariene V, Valiulis A, Kuna P, Samolinski B, Klimek L, Mösges R, Pfaar O, Shamai S, Roller-Wirnsberger RE, Tomazic PV, Ryan D, Sheikh A, Haahtela T, Toppila-Salmi S, Valovirta E, Cardona V, Mullol J, Valero A, Makris M, Papadopoulos NG, Prokopakis EP, Psarros F, Bachert C, Hellings PW, Pugin B, Bindslev-Jensen C, Eller E, Kull I, Melén E, Wickman M, De Vries G, van Eerd M, Agache I, Ansotegui IJ, Bosnic-Anticevich S, Cruz AA, Casale T, Ivancevich JC, Larenas-Linnemann DE, Sofiev M, Wallace D, Waserman S, Yorgancioglu A, Laune D, and Bousquet J
- Abstract
Background: The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users., Methods: The Allergy Diary-MASK-air-mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis., Results: 9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines., Conclusions: This study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.
- Published
- 2020
- Full Text
- View/download PDF
32. [The allergist facing the COVID-19 pandemic: What impact and what precautions should be taken?]
- Author
-
Fontaine JF, Fromentin E, Lefevre S, and Demoly P
- Abstract
In the unusual health environment of the COVID 19 pandemic, allergists must adapt their exercise and their office or clinic, by strengthening hygiene and distancing precautions. In case of sanitary containment telehealth can, in many cases, replace face-to-face visits. Nevertheless, each practitioner must define the contingency planning and the priorities according to his own practice and the epidemic context., (© 2020 Published by Elsevier Masson SAS.)
- Published
- 2020
- Full Text
- View/download PDF
33. RNA Sequencing of Human Peripheral Blood Cells Indicates Upregulation of Immune-Related Genes in Huntington's Disease.
- Author
-
Andrade-Navarro MA, Mühlenberg K, Spruth EJ, Mah N, González-López A, Andreani T, Russ J, Huska MR, Muro EM, Fontaine JF, Amstislavskiy V, Soldatov A, Nietfeld W, Wanker EE, and Priller J
- Abstract
Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a trinucleotide repeat expansion in the Huntingtin gene. As disease-modifying therapies for HD are being developed, peripheral blood cells may be used to indicate disease progression and to monitor treatment response. In order to investigate whether gene expression changes can be found in the blood of individuals with HD that distinguish them from healthy controls, we performed transcriptome analysis by next-generation sequencing (RNA-seq). We detected a gene expression signature consistent with dysregulation of immune-related functions and inflammatory response in peripheral blood from HD cases vs. controls, including induction of the interferon response genes, IFITM3, IFI6 and IRF7 . Our results suggest that it is possible to detect gene expression changes in blood samples from individuals with HD, which may reflect the immune pathology associated with the disease., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Andrade-Navarro, Mühlenberg, Spruth, Mah, González-López, Andreani, Russ, Huska, Muro, Fontaine, Amstislavskiy, Soldatov, Nietfeld, Wanker and Priller.)
- Published
- 2020
- Full Text
- View/download PDF
34. Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
- Author
-
Haenig C, Atias N, Taylor AK, Mazza A, Schaefer MH, Russ J, Riechers SP, Jain S, Coughlin M, Fontaine JF, Freibaum BD, Brusendorf L, Zenkner M, Porras P, Stroedicke M, Schnoegl S, Arnsburg K, Boeddrich A, Pigazzini L, Heutink P, Taylor JP, Kirstein J, Andrade-Navarro MA, Sharan R, and Wanker EE
- Subjects
- Humans, Brain physiopathology, Brain Mapping methods, Neurodegenerative Diseases genetics, Protein Aggregates genetics, Protein Interaction Mapping methods
- Abstract
Interactome maps are valuable resources to elucidate protein function and disease mechanisms. Here, we report on an interactome map that focuses on neurodegenerative disease (ND), connects ∼5,000 human proteins via ∼30,000 candidate interactions and is generated by systematic yeast two-hybrid interaction screening of ∼500 ND-related proteins and integration of literature interactions. This network reveals interconnectivity across diseases and links many known ND-causing proteins, such as α-synuclein, TDP-43, and ATXN1, to a host of proteins previously unrelated to NDs. It facilitates the identification of interacting proteins that significantly influence mutant TDP-43 and HTT toxicity in transgenic flies, as well as of ARF-GEP
100 that controls misfolding and aggregation of multiple ND-causing proteins in experimental model systems. Furthermore, it enables the prediction of ND-specific subnetworks and the identification of proteins, such as ATXN1 and MKL1, that are abnormally aggregated in postmortem brains of Alzheimer's disease patients, suggesting widespread protein aggregation in NDs., Competing Interests: Declaration of Interests The authors declare no competing interests., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
35. [Another pandemic!]
- Author
-
Fontaine JF and Bonniaud P
- Published
- 2020
- Full Text
- View/download PDF
36. Computational identification of cell-specific variable regions in ChIP-seq data.
- Author
-
Andreani T, Albrecht S, Fontaine JF, and Andrade-Navarro MA
- Subjects
- Animals, Binding Sites, Cell Line, Cell Line, Tumor, Chromatin metabolism, Embryonic Stem Cells metabolism, Evolution, Molecular, Genetic Variation, Genomics methods, Humans, K562 Cells, MCF-7 Cells, Mice, Nucleotides analysis, Principal Component Analysis, Promoter Regions, Genetic, R-Loop Structures, Chromatin Immunoprecipitation Sequencing, Transcription Factors metabolism
- Abstract
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is used to identify genome-wide DNA regions bound by proteins. Given one ChIP-seq experiment with replicates, binding sites not observed in all the replicates will usually be interpreted as noise and discarded. However, the recent discovery of high-occupancy target (HOT) regions suggests that there are regions where binding of multiple transcription factors can be identified. To investigate ChIP-seq variability, we developed a reproducibility score and a method that identifies cell-specific variable regions in ChIP-seq data by integrating replicated ChIP-seq experiments for multiple protein targets on a particular cell type. Using our method, we found variable regions in human cell lines K562, GM12878, HepG2, MCF-7 and in mouse embryonic stem cells (mESCs). These variable-occupancy target regions (VOTs) are CG dinucleotide rich, and show enrichment at promoters and R-loops. They overlap significantly with HOT regions, but are not blacklisted regions producing non-specific binding ChIP-seq peaks. Furthermore, in mESCs, VOTs are conserved among placental species suggesting that they could have a function important for this taxon. Our method can be useful to point to such regions along the genome in a given cell type of interest, to improve the downstream interpretative analysis before follow-up experiments., (© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2020
- Full Text
- View/download PDF
37. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence.
- Author
-
Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, Klimek L, Pfaar O, Wallace D, Ansotegui I, Agache I, Bedbrook A, Bergmann KC, Bewick M, Bonniaud P, Bosnic-Anticevich S, Bossé I, Bouchard J, Boulet LP, Brozek J, Brusselle G, Calderon MA, Canonica WG, Caraballo L, Cardona V, Casale T, Cecchi L, Chu DK, Costa EM, Cruz AA, Czarlewski W, D'Amato G, Devillier P, Dykewicz M, Ebisawa M, Fauquert JL, Fokkens WJ, Fonseca JA, Fontaine JF, Gemicioglu B, van Wijk RG, Haahtela T, Halken S, Ierodiakonou D, Iinuma T, Ivancevich JC, Jutel M, Kaidashev I, Khaitov M, Kalayci O, Kleine Tebbe J, Kowalski ML, Kuna P, Kvedariene V, La Grutta S, Larenas-Linnemann D, Lau S, Laune D, Le L, Lieberman P, Lodrup Carlsen KC, Lourenço O, Marien G, Carreiro-Martins P, Melén E, Menditto E, Neffen H, Mercier G, Mosgues R, Mullol J, Muraro A, Namazova L, Novellino E, O'Hehir R, Okamoto Y, Ohta K, Park HS, Panzner P, Passalacqua G, Pham-Thi N, Price D, Roberts G, Roche N, Rolland C, Rosario N, Ryan D, Samolinski B, Sanchez-Borges M, Scadding GK, Shamji MH, Sheikh A, Bom AT, Toppila-Salmi S, Tsiligianni I, Valentin-Rostan M, Valiulis A, Valovirta E, Ventura MT, Walker S, Waserman S, Yorgancioglu A, and Zuberbier T
- Subjects
- Humans, Practice Guidelines as Topic, Algorithms, Asthma diagnosis, Asthma immunology, Asthma therapy, Evidence-Based Practice, Rhinitis, Allergic diagnosis, Rhinitis, Allergic immunology, Rhinitis, Allergic therapy
- Abstract
The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm., (Copyright © 2019 American Academy of Allergy, Asthma & Immunology. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
38. 2019 ARIA Care pathways for allergen immunotherapy.
- Author
-
Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG, Tsiligianni I, Agache I, Anto JM, Bachert C, Bedbrook A, Bergmann KC, Bosnic-Anticevich S, Bosse I, Brozek J, Calderon MA, Canonica GW, Caraballo L, Cardona V, Casale T, Cecchi L, Chu D, Costa E, Cruz AA, Czarlewski W, Durham SR, Du Toit G, Dykewicz M, Ebisawa M, Fauquert JL, Fernandez-Rivas M, Fokkens WJ, Fonseca J, Fontaine JF, Gerth van Wijk R, Haahtela T, Halken S, Hellings PW, Ierodiakonou D, Iinuma T, Ivancevich JC, Jacobsen L, Jutel M, Kaidashev I, Khaitov M, Kalayci O, Kleine Tebbe J, Klimek L, Kowalski ML, Kuna P, Kvedariene V, La Grutta S, Larenas-Linemann D, Lau S, Laune D, Le L, Lodrup Carlsen K, Lourenço O, Malling HJ, Marien G, Menditto E, Mercier G, Mullol J, Muraro A, O'Hehir R, Okamoto Y, Pajno GB, Park HS, Panzner P, Passalacqua G, Pham-Thi N, Roberts G, Pawankar R, Rolland C, Rosario N, Ryan D, Samolinski B, Sanchez-Borges M, Scadding G, Shamji MH, Sheikh A, Sturm GJ, Todo Bom A, Toppila-Salmi S, Valentin-Rostan M, Valiulis A, Valovirta E, Ventura MT, Wahn U, Walker S, Wallace D, Waserman S, Yorgancioglu A, and Zuberbier T
- Subjects
- Allergens administration & dosage, Allergens immunology, Animals, Asthma epidemiology, Asthma immunology, Attitude of Health Personnel, Biomarkers, Clinical Decision-Making, Comorbidity, Cost of Illness, Cost-Benefit Analysis, Disease Management, Disease Susceptibility, Humans, Practice Guidelines as Topic, Precision Medicine methods, Rhinitis, Allergic epidemiology, Rhinitis, Allergic immunology, Treatment Outcome, Asthma therapy, Critical Pathways, Desensitization, Immunologic adverse effects, Desensitization, Immunologic methods, Rhinitis, Allergic therapy
- Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients., (© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
39. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases.
- Author
-
Bousquet JJ, Schünemann HJ, Togias A, Erhola M, Hellings PW, Zuberbier T, Agache I, Ansotegui IJ, Anto JM, Bachert C, Becker S, Bedolla-Barajas M, Bewick M, Bosnic-Anticevich S, Bosse I, Boulet LP, Bourrez JM, Brusselle G, Chavannes N, Costa E, Cruz AA, Czarlewski W, Fokkens WJ, Fonseca JA, Gaga M, Haahtela T, Illario M, Klimek L, Kuna P, Kvedariene V, Le LTT, Larenas-Linnemann D, Laune D, Lourenço OM, Menditto E, Mullol J, Okamoto Y, Papadopoulos N, Pham-Thi N, Picard R, Pinnock H, Roche N, Roller-Wirnsberger RE, Rolland C, Samolinski B, Sheikh A, Toppila-Salmi S, Tsiligianni I, Valiulis A, Valovirta E, Vasankari T, Ventura MT, Walker S, Williams S, Akdis CA, Annesi-Maesano I, Arnavielhe S, Basagana X, Bateman E, Bedbrook A, Bennoor KS, Benveniste S, Bergmann KC, Bialek S, Billo N, Bindslev-Jensen C, Bjermer L, Blain H, Bonini M, Bonniaud P, Bouchard J, Briedis V, Brightling CE, Brozek J, Buhl R, Buonaiuto R, Canonica GW, Cardona V, Carriazo AM, Carr W, Cartier C, Casale T, Cecchi L, Cepeda Sarabia AM, Chkhartishvili E, Chu DK, Cingi C, Colgan E, de Sousa JC, Courbis AL, Custovic A, Cvetkosvki B, D'Amato G, da Silva J, Dantas C, Dokic D, Dauvilliers Y, Dedeu A, De Feo G, Devillier P, Di Capua S, Dykewickz M, Dubakiene R, Ebisawa M, El-Gamal Y, Eller E, Emuzyte R, Farrell J, Fink-Wagner A, Fiocchi A, Fontaine JF, Gemicioğlu B, Schmid-Grendelmeir P, Gamkrelidze A, Garcia-Aymerich J, Gomez M, González Diaz S, Gotua M, Guldemond NA, Guzmán MA, Hajjam J, O'B Hourihane J, Humbert M, Iaccarino G, Ierodiakonou D, Illario M, Ivancevich JC, Joos G, Jung KS, Jutel M, Kaidashev I, Kalayci O, Kardas P, Keil T, Khaitov M, Khaltaev N, Kleine-Tebbe J, Kowalski ML, Kritikos V, Kull I, Leonardini L, Lieberman P, Lipworth B, Lodrup Carlsen KC, Loureiro CC, Louis R, Mair A, Marien G, Mahboub B, Malva J, Manning P, De Manuel Keenoy E, Marshall GD, Masjedi MR, Maspero JF, Mathieu-Dupas E, Matricardi PM, Melén E, Melo-Gomes E, Meltzer EO, Menditto E, Mercier J, Miculinic N, Mihaltan F, Milenkovic B, Moda G, Mogica-Martinez MD, Mohammad Y, Montefort S, Monti R, Morais-Almeida M, Mösges R, Münter L, Muraro A, Murray R, Naclerio R, Napoli L, Namazova-Baranova L, Neffen H, Nekam K, Neou A, Novellino E, Nyembue D, O'Hehir R, Ohta K, Okubo K, Onorato G, Ouedraogo S, Pali-Schöll I, Palkonen S, Panzner P, Park HS, Pépin JL, Pereira AM, Pfaar O, Paulino E, Phillips J, Picard R, Plavec D, Popov TA, Portejoie F, Price D, Prokopakis EP, Pugin B, Raciborski F, Rajabian-Söderlund R, Reitsma S, Rodo X, Romano A, Rosario N, Rottem M, Ryan D, Salimäki J, Sanchez-Borges MM, Sisul JC, Solé D, Somekh D, Sooronbaev T, Sova M, Spranger O, Stellato C, Stelmach R, Suppli Ulrik C, Thibaudon M, To T, Todo-Bom A, Tomazic PV, Valero AA, Valenta R, Valentin-Rostan M, van der Kleij R, Vandenplas O, Vezzani G, Viart F, Viegi G, Wallace D, Wagenmann M, Wang Y, Waserman S, Wickman M, Williams DM, Wong G, Wroczynski P, Yiallouros PK, Yorgancioglu A, Yusuf OM, Zar HJ, Zeng S, Zernotti M, Zhang L, Zhong NS, and Zidarn M
- Abstract
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy., Main Body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care., Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement., Competing Interests: Competing interestsDr. Ansotegui reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, outside the submitted work. Dr. Bosnic-Anticevich reports grants from TEVA, personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, Sanofi, Mylan, outside the submitted work. Dr. Bousquet reports personal fees and others from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, others from Kyomed, outside the submitted work. Dr. Boulet reports and Disclosure of potential conflicts of interest—last 3 years. Research grants for participation to multicentre studies, AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi, Takeda. Support for research projects introduced by the investigator AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Takeda. Consulting and advisory boards Astra Zeneca, Novartis, Methapharm. Royalties Co-author of “Up-To-Date” (occupational asthma). Nonprofit grants for production of educational materials AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis. Conference fees AstraZeneca, GlaxoSmithKline, Merck, Novartis. Support for participation in conferences and meetings Novartis, Takeda. Other participations Past president and Member of the Canadian Thoracic Society Respiratory Guidelines Committee; Chair of the Board of Directors of the Global Initiative for Asthma (GINA). Chair of Global Initiative for Asthma (GINA) Guidelines Dissemination and Implementation Committee; Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; Member of scientific committees for the American College of Chest Physicians, American Thoracic Society, European Respiratory Society and the World Allergy Organization; 1st Vice-President of the Global Asthma Organization “InterAsma”. Dr. Casale reports grants and non-financial support from Stallergenes, outside the submitted work. Dr. Cruz reports grants and personal fees from GlaxoSmithKline, personal fees from Boehrinher Ingelheim, AstraZeneca, Novartis, Merk, Sharp & Dohme, MEDA Pharma, EUROFARMA, Sanofi Aventis, outside the submitted work. Dr. Ebisawa reports personal fees from DBV Technologies, Mylan EPD maruho, Shionogi & CO., Ltd., Kyorin Pharmaceutical Co., Ltd., Thermofisher Diagnostics, Pfizer, Beyer, Nippon Chemifar, Takeda Pharmaceutical Co., Ltd., MSD, outside the submitted work. Dr. Ivancevich reports personal fees from Euro Farma Argentina, Faes Farma, non-financial support from Laboratorios Casasco, outside the submitted work. Dr. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma, outside the submitted work. Dr. Klimek reports grants and personal fees from ALK Abelló, Denmark, Novartis, Switzerland, Allergopharma, Germany, Bionorica, Germany, GSK, Great Britain, Lofarma, Italy, personal fees from MEDA, Sweden, Boehringer Ingelheim, Germany, grants from Biomay, Austria, HAL, Netherlands, LETI, Spain, Roxall, Germany, Bencard, Great Britain, outside the submitted work. V.KV has received payment for consultancy from GSK and for lectures from StallergensGreer, Berlin-CHemie and sponsorship from MYLAN for in the following professional training: ARIA masterclass in allergic rhinitis participation. Dr. Larenas Linnemann reports personal fees from GSK, Astrazeneca, MEDA, Boehringer Ingelheim, Novartis, Grunenthal, UCB, Amstrong, Siegfried, DBV Technologies, MSD, Pfizer., grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Chiesi, Boehringer Ingelheim, outside the submitted work. Dr. Mösges reports personal fees from ALK, grants from ASIT biotech, Leti, BitopAG, Hulka, Ursapharm, Optima; personal fees from allergopharma, Nuvo, Meda, Friulchem, Hexal, Servier, Bayer, Johnson & Johnson, Klosterfrau, GSK, MSD, FAES, Stada, UCB, Allergy Therapeutics; grants and personal fees from Bencard, Stallergenes; grants, personal fees and non-financial support from Lofarma; non-financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero; personal fees and non-financial support from Novartis; Dr. Okamoto reports personal fees from Eizai Co., Ltd., Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Kyowa Co., Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm, outside the submitted work. Dr. Papadopoulos reports grants from Gerolymatos, personal fees from Hal Allergy B.V., Novartis Pharma AG, Menarini, Hal Allergy B.V., outside the submitted work. Dr. Pépin reports grants from AIR LIQUIDE FOUNDATION, AGIR à dom, ASTRA ZENECA, FISHER & PAYKEL, MUTUALIA, PHILIPS, RESMED, VITALAIRE, other from AGIR à dom, ASTRA ZENECA, BOEHRINGER INGELHEIM, JAZZ PHARMACEUTICAL, NIGHT BALANCE, PHILIPS, RESMED, SEFAM, outside the submitted work. Dr. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, ASIT Biotech Tools S.A, Laboratorios LETI/LETI Pharma, Anergis S.A., grants from Nuvo, Circassia, Glaxo Smith Kline, personal fees from Novartis Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, Indoor Biotechnologies, grants from, outside the submitted work. Dr. Todo-Bom reports grants and personal fees from Novartis, Mundipharma, GSK Teva Pharma, personal fees from AstraZeneca, grants from Leti, outside the submitted work. Dr. Tsiligianni reports advisory boards from Boehringer Ingelheim and Novartis and a grant from GSK, outside the submitted work. Dr. Wallace reports and Indicates that she is the co-chair of the Joint Task Force on Practice Parameters, a task force composed of 12 members of the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology. Dr. Waserman reports other from CSL Behring, Shire, AstraZeneca,Teva, Meda, Merck, outside the submitted work. Dr. Zuberbier reports and Organizational affiliations: Commitee member: WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF). Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).
- Published
- 2019
- Full Text
- View/download PDF
40. TAF-ChIP: an ultra-low input approach for genome-wide chromatin immunoprecipitation assay.
- Author
-
Akhtar J, More P, Albrecht S, Marini F, Kaiser W, Kulkarni A, Wojnowski L, Fontaine JF, Andrade-Navarro MA, Silies M, and Berger C
- Subjects
- Animals, Epigenesis, Genetic, High-Throughput Nucleotide Sequencing, Humans, K562 Cells, Signal-To-Noise Ratio, Software, Whole Genome Sequencing, Chromatin Immunoprecipitation Sequencing methods, Drosophila genetics, Histones metabolism
- Abstract
Chromatin immunoprecipitation (ChIP) followed by next generation sequencing (ChIP-Seq) is a powerful technique to study transcriptional regulation. However, the requirement of millions of cells to generate results with high signal-to-noise ratio precludes it in the study of small cell populations. Here, we present a tagmentation-assisted fragmentation ChIP (TAF-ChIP) and sequencing method to generate high-quality histone profiles from low cell numbers. The data obtained from the TAF-ChIP approach are amenable to standard tools for ChIP-Seq analysis, owing to its high signal-to-noise ratio. The epigenetic profiles from TAF-ChIP approach showed high agreement with conventional ChIP-Seq datasets, thereby underlining the utility of this approach., (© 2019 Akhtar et al.)
- Published
- 2019
- Full Text
- View/download PDF
41. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study.
- Author
-
Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S, Bedbrook A, Onorato GL, Czarlewski W, Murray R, Almeida R, Fonseca J, Costa E, Malva J, Morais-Almeida M, Pereira AM, Todo-Bom A, Menditto E, Stellato C, Ventura MT, Cruz AA, Stelmach R, da Silva J, Larenas-Linnemann D, Fuentes-Pérez JM, Huerta-Villalobos YR, Emuzyte R, Kvedariene V, Valiulis A, Kuna P, Samolinski B, Klimek L, Mösges R, Pfaar O, Shamai S, Annesi-Maesano I, Bosse I, Demoly P, Fontaine JF, Cardona V, Mullol J, Valero A, Roller-Wirnsberger RE, Tomazic PV, Chavannes NH, Fokkens WJ, Reitsma S, Bewick M, Ryan D, Sheikh A, Haahtela T, Toppila-Salmi S, Valovirta E, Makris M, Papadopoulos NG, Prokopakis EP, Psarros F, Cingi C, Gemicioğlu B, Yorgancioglu A, Bosnic-Anticevich S, O'Hehir RE, Bachert C, Hellings PW, Pugin B, Bindslev-Jensen C, Eller E, Kull I, Melén E, Wickman M, De Vries G, van Eerd M, Agache I, Ansotegui IJ, Dykewicz MS, Casale T, Wallace D, Waserman S, Laune D, and Bousquet J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Efficiency, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Symptom Assessment, Visual Analog Scale, Young Adult, Adrenal Cortex Hormones therapeutic use, Histamine H1 Antagonists therapeutic use, Mobile Applications, Rhinitis, Allergic drug therapy
- Abstract
Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control., Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR., Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H
1 -antihistamines were studied., Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H1 -antihistamines were found., Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible., (Copyright © 2019 American Academy of Allergy, Asthma & Immunology. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
42. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study.
- Author
-
Menditto E, Costa E, Midão L, Bosnic-Anticevich S, Novellino E, Bialek S, Briedis V, Mair A, Rajabian-Soderlund R, Arnavielhe S, Bedbrook A, Czarlewski W, Annesi-Maesano I, Anto JM, Devillier P, De Vries G, Keil T, Sheikh A, Orlando V, Larenas-Linnemann D, Cecchi L, De Feo G, Illario M, Stellato C, Fonseca J, Malva J, Morais-Almeida M, Pereira AM, Todo-Bom AM, Kvedariene V, Valiulis A, Bergmann KC, Klimek L, Mösges R, Pfaar O, Zuberbier T, Cardona V, Mullol J, Papadopoulos NG, Prokopakis EP, Bewick M, Ryan D, Roller-Wirnsberger RE, Tomazic PV, Cruz AA, Kuna P, Samolinski B, Fokkens WJ, Reitsma S, Bosse I, Fontaine JF, Laune D, Haahtela T, Toppila-Salmi S, Bachert C, Hellings PW, Melén E, Wickman M, Bindslev-Jensen C, Eller E, O'Hehir RE, Cingi C, Gemicioğlu B, Kalayci O, Ivancevich JC, and Bousquet J
- Subjects
- Adult, Aged, Cross-Sectional Studies, Female, Humans, Male, Medical Records, Middle Aged, Patient Outcome Assessment, Rhinitis, Allergic diagnosis, Rhinitis, Allergic therapy, Surveys and Questionnaires, Cell Phone Use, Medication Adherence, Mobile Applications, Rhinitis, Allergic epidemiology
- Abstract
Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries., Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App., Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach., Results: A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data. About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users., Conclusion and Clinical Relevance: Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
43. Development of algorithms for the diagnosis and management of acute allergy in primary practice.
- Author
-
Demoly P, Chabane H, Fontaine JF, de Boissieu D, Ryan D, Angier E, and Just J
- Abstract
Most patients presenting with allergies are first seen in the primary care setting. However, inadequacies in training and available guidance for general practitioners (GP) have been identified as significantly impacting the quality of care for these patients, resulting in inefficient use of healthcare resources. To address the lack of available guidance, a working group of French allergists has developed a series of online tools aimed at GPs. The expert panel developed algorithms for the diagnosis and treatment of common allergies by incorporating deliberations based on clinical guidelines and experience. In addition, they developed tables of common symptoms and detailed clinical cases that guide GPs through the typical decisions they are faced with in line with current best practice. These tools translate evidence-based recommendations from international clinical guidelines, outlining the key steps involved and assisting the physician in making decisions at each step. In addition to targeting improvements in diagnosis and standard of primary care, the tools also aim to reduce the burden on specialist allergy services by enabling GPs to diagnose and treat mild and moderate allergies, referring only severe and/or atypical cases to secondary care. The tools are adapted to the high primary care workload, enabling the physician to access essential information rapidly without unnecessary referrals to specialist allergy services.
- Published
- 2019
- Full Text
- View/download PDF
44. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.
- Author
-
Bousquet J, Bedbrook A, Czarlewski W, Onorato GL, Arnavielhe S, Laune D, Mathieu-Dupas E, Fonseca J, Costa E, Lourenço O, Morais-Almeida M, Todo-Bom A, Illario M, Menditto E, Canonica GW, Cecchi L, Monti R, Napoli L, Ventura MT, De Feo G, Fokkens WJ, Chavannes NH, Reitsma S, Cruz AA, da Silva J, Serpa FS, Larenas-Linnemann D, Fuentes Perez JM, Huerta-Villalobos YR, Rivero-Yeverino D, Rodriguez-Zagal E, Valiulis A, Dubakiene R, Emuzyte R, Kvedariene V, Annesi-Maesano I, Blain H, Bonniaud P, Bosse I, Dauvilliers Y, Devillier P, Fontaine JF, Pépin JL, Pham-Thi N, Portejoie F, Picard R, Roche N, Rolland C, Schmidt-Grendelmeier P, Kuna P, Samolinski B, Anto JM, Cardona V, Mullol J, Pinnock H, Ryan D, Sheikh A, Walker S, Williams S, Becker S, Klimek L, Pfaar O, Bergmann KC, Mösges R, Zuberbier T, Roller-Wirnsberger RE, Tomazic PV, Haahtela T, Salimäki J, Toppila-Salmi S, Valovirta E, Vasankari T, Gemicioğlu B, Yorgancioglu A, Papadopoulos NG, Prokopakis EP, Tsiligianni IG, Bosnic-Anticevich S, O'Hehir R, Ivancevich JC, Neffen H, Zernotti ME, Kull I, Melén E, Wickman M, Bachert C, Hellings PW, Brusselle G, Palkonen S, Bindslev-Jensen C, Eller E, Waserman S, Boulet LP, Bouchard J, Chu DK, Schünemann HJ, Sova M, De Vries G, van Eerd M, Agache I, Ansotegui IJ, Bewick M, Casale T, Dykewick M, Ebisawa M, Murray R, Naclerio R, Okamoto Y, and Wallace DV
- Abstract
Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases., Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients., Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors., Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered., Eu Grants 2018: MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour)., Lessons Learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
- Published
- 2019
- Full Text
- View/download PDF
45. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology.
- Author
-
Bousquet J, Hellings PW, Agache I, Amat F, Annesi-Maesano I, Ansotegui IJ, Anto JM, Bachert C, Bateman ED, Bedbrook A, Bennoor K, Bewick M, Bindslev-Jensen C, Bosnic-Anticevich S, Bosse I, Brozek J, Brussino L, Canonica GW, Cardona V, Casale T, Cepeda Sarabia AM, Chavannes NH, Cecchi L, Correia de Sousa J, Costa E, Cruz AA, Czarlewski W, De Carlo G, De Feo G, Demoly P, Devillier P, Dykewicz MS, El-Gamal Y, Eller EE, Fonseca JA, Fontaine JF, Fokkens WJ, Guzmán MA, Haahtela T, Illario M, Ivancevich JC, Just J, Kaidashev I, Khaitov M, Kalayci O, Keil T, Klimek L, Kowalski ML, Kuna P, Kvedariene V, Larenas-Linnemann D, Laune D, Le LTT, Carlsen KL, Lourenço O, Mahboub B, Mair A, Menditto E, Milenkovic B, Morais-Almeida M, Mösges R, Mullol J, Murray R, Naclerio R, Namazova-Baranova L, Novellino E, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Onorato GL, Palkonen S, Panzner P, Papadopoulos NG, Park HS, Paulino E, Pawankar R, Pfaar O, Plavec D, Popov TA, Potter P, Prokopakis EP, Rottem M, Ryan D, Salimäki J, Samolinski B, Sanchez-Borges M, Schunemann HJ, Sheikh A, Sisul JC, Rajabian-Söderlund R, Sooronbaev T, Stellato C, To T, Todo-Bom AM, Tomazic PV, Toppila-Salmi S, Valero A, Valiulis A, Valovirta E, Ventura MT, Wagenmann M, Wang Y, Wallace D, Waserman S, Wickman M, Yorgancioglu A, Zhang L, Zhong N, Zidarn M, and Zuberbier T
- Subjects
- Change Management, Humans, Medical Records, Asthma diagnosis, Asthma therapy, Multimorbidity, Rhinitis, Allergic diagnosis, Rhinitis, Allergic therapy, Telemedicine
- Abstract
Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional., (Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
46. Literature optimized integration of gene expression for organ-specific evaluation of toxicogenomics datasets.
- Author
-
Taškova K, Fontaine JF, Mrowka R, and Andrade-Navarro MA
- Subjects
- Animals, Gene Expression Profiling, Humans, ROC Curve, Rats, Databases, Genetic, Gene Expression Regulation, Organ Specificity genetics, Publications, Toxicogenetics
- Abstract
The study of drug toxicity in human organs is complicated by their complex inter-relations and by the obvious difficulty to testing drug effects on biologically relevant material. Animal models and human cell cultures offer alternatives for systematic and large-scale profiling of drug effects on gene expression level, as typically found in the so-called toxicogenomics datasets. However, the complexity of these data, which includes variable drug doses, time points, and experimental setups, makes it difficult to choose and integrate the data, and to evaluate the appropriateness of one or another model system to study drug toxicity (of particular drugs) of particular human organs. Here, we define a protocol to integrate drug-wise rankings of gene expression changes in toxicogenomics data, which we apply to the TG-GATEs dataset, to prioritize genes for association to drug toxicity in liver or kidney. Contrast of the results with sets of known human genes associated to drug toxicity in the literature allows to compare different rank aggregation approaches for the task at hand. Collectively, ranks from multiple models point to genes not previously associated to toxicity, notably, the PCNA clamp associated factor (PCLAF), and genes regulated by the master regulator of the antioxidant response NFE2L2, such as NQO1 and SRXN1. In addition, comparing gene ranks from different models allowed us to evaluate striking differences in terms of toxicity-associated genes between human and rat hepatocytes or between rat liver and rat hepatocytes. We interpret these results to point to the different molecular functions associated to organ toxicity that are best described by each model. We conclude that the expected production of toxicogenomics panels with larger numbers of drugs and models, in combination with the ongoing increase of the experimental literature in organ toxicity, will lead to increasingly better associations of genes for organism toxicity., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
47. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence.
- Author
-
Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E, Murray R, Onorato GL, Pépin JL, Picard R, Portejoie F, Costa E, Fonseca J, Lourenço O, Morais-Almeida M, Todo-Bom A, Cruz AA, da Silva J, Serpa FS, Illario M, Menditto E, Cecchi L, Monti R, Napoli L, Ventura MT, De Feo G, Larenas-Linnemann D, Fuentes Perez M, Huerta Villabolos YR, Rivero-Yeverino D, Rodriguez-Zagal E, Amat F, Annesi-Maesano I, Bosse I, Demoly P, Devillier P, Fontaine JF, Just J, Kuna TP, Samolinski B, Valiulis A, Emuzyte R, Kvedariene V, Ryan D, Sheikh A, Schmidt-Grendelmeier P, Klimek L, Pfaar O, Bergmann KC, Mösges R, Zuberbier T, Roller-Wirnsberger RE, Tomazic P, Fokkens WJ, Chavannes NH, Reitsma S, Anto JM, Cardona V, Dedeu T, Mullol J, Haahtela T, Salimäki J, Toppila-Salmi S, Valovirta E, Gemicioğlu B, Yorgancioglu A, Papadopoulos N, Prokopakis EP, Bosnic-Anticevich S, O'Hehir R, Ivancevich JC, Neffen H, Zernotti E, Kull I, Melen E, Wickman M, Bachert C, Hellings P, Palkonen S, Bindslev-Jensen C, Eller E, Waserman S, Sova M, De Vries G, van Eerd M, Agache I, Casale T, Dykewickz M, Naclerio RN, Okamoto Y, and Wallace DV
- Abstract
mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app ( the Allergy Diary , Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary .
- Published
- 2018
- Full Text
- View/download PDF
48. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study.
- Author
-
Bousquet J, Devillier P, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M, Murray R, Canonica GW, Illario M, Menditto E, Passalacqua G, Stellato C, Triggiani M, Carreiro-Martins P, Fonseca J, Morais Almeida M, Nogueira-Silva L, Pereira AM, Todo Bom A, Bosse I, Caimmi D, Demoly P, Fontaine JF, Just J, Onorato GL, Kowalski ML, Kuna P, Samolinski B, Anto JM, Mullol J, Valero A, Tomazic PV, Bergmann KC, Keil T, Klimek L, Mösges R, Shamai S, Zuberbier T, Murphy E, McDowall P, Price D, Ryan D, Sheikh A, Chavannes NH, Fokkens WJ, Kvedariene V, Valiulis A, Bachert C, Hellings PW, Kull I, Melen E, Wickman M, Bindslev-Jensen C, Eller E, Haahtela T, Papadopoulos NG, Annesi-Maesano I, Bewick M, Bosnic-Anticevich S, Cruz AA, De Vries G, Gemicioglu B, Larenas-Linnemann D, Laune D, Mathieu-Dupas E, O'Hehir RE, Pfaar O, Portejoie F, Siroux V, Spranger O, Valovirta E, VandenPlas O, and Yorgancioglu A
- Subjects
- Adult, Combined Modality Therapy, Disease Management, Drug Prescriptions statistics & numerical data, Female, Global Health, Humans, Male, Medication Adherence, Middle Aged, Pilot Projects, Prospective Studies, Randomized Controlled Trials as Topic, Research Design, Rhinitis, Allergic epidemiology, Rhinitis, Allergic prevention & control, Young Adult, Mobile Applications, Rhinitis, Allergic therapy
- Abstract
Background: Large observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect "real-world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real-life treatment of allergic rhinitis (AR) using mobile technology., Methods: A mobile phone app (Allergy Diary, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries., Results: A total of 2871 users filled in 17 091 days of VAS in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control)., Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings, and generates new hypotheses., (© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
49. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study.
- Author
-
Samreth D, Arnavielhe S, Ingenrieth F, Bedbrook A, Onorato GL, Murray R, Almeida R, Mizani MA, Fonseca J, Costa E, Malva J, Morais-Almeida M, Pereira AM, Todo-Bom A, Menditto E, Stellato C, Ventura MT, Larenas-Linnemann D, Fuentes-Pérez JM, Huerta-Villalobos YR, Cruz AA, Stelmach R, da Silva J, Emuzyte R, Kvedariene V, Valiulis A, Annesi-Maesano I, Bosse I, Demoly P, Devillier P, Fontaine JF, Kuna P, Samolinski B, Klimek L, Mösges R, Pfaar O, Shamai S, Bewick M, Ryan D, Sheikh A, Anto JM, Cardona V, Mullol J, Valero A, Chavannes NH, Fokkens WJ, Reitsma S, Roller-Wirnsberger RE, Tomazic PV, Haahtela T, Toppila-Salmi S, Valovirta E, Makris M, Papadopoulos NG, Prokopakis EP, Psarros F, Gemicioğlu B, Yorgancioglu A, Bindslev-Jensen C, Eller E, Kull I, Wickman M, Bachert C, Hellings PW, Pugin B, Bosnic-Anticevich S, O'Hehir RE, Kolek V, Sova M, Wehner K, De Vries G, van Eerd M, Laune D, Wittmann J, Bousquet J, and Poncelet P
- Abstract
Background: Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission's Article 29 Working Party stated that geolocation information is personal data.To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method., Methods: Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization)., Results: Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58.5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users' life privacy., Discussion: k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases., Competing Interests: No ethical committee was required for the study.Not needed. JB reports personal fees and other from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, other from Kyomed, outside the submitted work.RA reports grants from North Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL2020 Partnership Agreement and through the European Regional Development Fund (ERDF), during the conduct of the study.AC reports grants and personal fees from GlaxoSmithKline, personal fees from Boehringer Ingelheim, MEDA Pharma, CHIESI, AstraZeneca, om Merck, Sharp & Dohme, Novartis EUROFARMA outside the submitted work.H reports personal fees from Munidpharma, Novartis, OrionPharma, outside the submitted work. PK reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca, Chiesi, FAES, Berlin Chemie, Novartis, Polpharma, Allergopharma, outside the submitted work.V.K has received payment for consultancy from GSK and for lectures from StallergensGreer, Berlin-CHemie outsaide the submitted work.LL reports personal fees from MSD, Pfizer, GSK, Astrazeneca, MEDA, Boehringer Ingelheim, Novartis, Grunenthal, UCB, TEVA, Amstrong, Siegfried, DBV Technologies, grants from Sanofi, Pfizer, Astrazeneca, Novartis, UCB, outside the submitted work.RM reports personal fees from ALK, allergopharma, Allergy Therapeutics, Bayer, Friulchem, FAES, GSK, Hexal, Servier, Klosterfrau, MSD, Johnson&Johnson, Meda, Stada, UCB, Nuvo; grants and personal fees from Bencard, Stallergenes; grants from Leti, Optima, ASIT biotech, BitopAG, Hulka, Ursapharm; grants, personal fees and non-financial support from Lofarma; non-financial support from Atmos, Roxall, Bionorica, Otonomy, Ferrero; personal fees and non-financial support from Novartis; outside the submitted work.NGP reports personal fees from Abbvie Novartis, Faes Farma, BIOMAY, HAL, Nutricia Research, Menarini, Novartis, MEDA, MSD, Omega Pharma, Danone, grants from Menarini, outside the submitted work.0P reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., grants from Biomay, Nuvo, Circassia, Glaxo Smith Kline, personal fees from Novartis Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, Indoor Biotechnologies, grants from, outside the submitted work.RS reports grants from São Paulo Research Foundation, MSD, grants and personal fees from Novartis, grants, personal fees and non-financial support from AstraZeneca, Chiesi, personal fees and non-financial support from Boheringer Ingelheim, outside the submitted work.TBAM reports grants and personal fees from Novartis, Boehringer Ingelheim, Mundipharma, GSK (GlaxoSmithKline), personal fees from Teva Pharma, AstraZeneca, grants from Leti, outside the submitted work. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Published
- 2018
- Full Text
- View/download PDF
50. Validation of the Strain Assessment of a Phantom of Abdominal Aortic Aneurysm: Comparison of Results Obtained From Magnetic Resonance Imaging and Stereovision Measurements.
- Author
-
Wang Y, Joannic D, Juillion P, Monnet A, Delassus P, Lalande A, and Fontaine JF
- Subjects
- Aged, Aortic Aneurysm, Abdominal physiopathology, Biomechanical Phenomena, Computer Simulation, Humans, Hydrodynamics, Imaging, Three-Dimensional, Male, Models, Cardiovascular, Tomography, X-Ray Computed, Aortic Aneurysm, Abdominal diagnostic imaging, Magnetic Resonance Imaging instrumentation, Phantoms, Imaging, Stress, Mechanical
- Abstract
Predicting aortic aneurysm ruptures is a complex problem that has been investigated by many research teams over several decades. Work on this issue is notably complex and involves both the mechanical behavior of the artery and the blood flow. Magnetic resonance imaging (MRI) can provide measurements concerning the shape of an organ and the blood that flows through it. Measuring local distortion of the artery wall is the first essential factor to evaluate in a ruptured artery. This paper aims to demonstrate the feasibility of this measure using MRI on a phantom of an abdominal aortic aneurysm (AAA) with realistic shape. The aortic geometry is obtained from a series of cine-MR images and reconstructed using Mimics software. From 4D flow and MRI measurements, the field of velocity is determined and introduced into a computational fluid dynamic (CFD) model to determine the mechanical boundaries applied on the wall artery (pressure and ultimately wall shear stress (WSS)). These factors are then converted into a solid model that enables wall deformations to be calculated. This approach was applied to a silicone phantom model of an AAA reconstructed from a patient's computed tomography-scan examination. The calculated deformations were then compared to those obtained in identical conditions by stereovision. The results of both methods were found to be close. Deformations of the studied AAA phantom with complex shape were obtained within a gap of 12% by modeling from MR data.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.